BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-S64. [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012] [Cited by in Crossref: 1011] [Cited by in F6Publishing: 958] [Article Influence: 168.5] [Reference Citation Analysis]
Number Citing Articles
1 Ustyol A, Aycan Ustyol E, Gurdol F, Kokali F, Bekpınar S. P-selectin, endocan, and some adhesion molecules in obese children and adolescents with non-alcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation 2017;77:205-9. [DOI: 10.1080/00365513.2017.1292363] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
2 Janssen A, Grobbee DE, Dendale P. Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease. Eur J Prev Cardiol 2020;27:1059-63. [PMID: 31801050 DOI: 10.1177/2047487319891783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang X, Bai R, Jia Y, Zong J, Wang Y, Dong Y. The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus. Int J Diabetes Dev Ctries 2020;40:491-9. [DOI: 10.1007/s13410-020-00857-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li K, Zhang K, Wang H, Wu Y, Chen N, Chen J, Qiu C, Cai P, Li M, Liang X, Su D. Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice. Metabolism 2021;114:154349. [PMID: 32888949 DOI: 10.1016/j.metabol.2020.154349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Higarza SG, Arboleya S, Gueimonde M, Gómez-Lázaro E, Arias JL, Arias N. Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits. PLoS One 2019;14:e0223019. [PMID: 31539420 DOI: 10.1371/journal.pone.0223019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
6 Derra A, Bator M, Menżyk T, Kukla M. Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. Clin Exp Hepatol 2018;4:55-71. [PMID: 29904722 DOI: 10.5114/ceh.2018.75955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Montesano A, Senesi P, Vacante F, Mollica G, Benedini S, Mariotti M, Luzi L, Terruzzi I. L-Carnitine counteracts in vitro fructose-induced hepatic steatosis through targeting oxidative stress markers. J Endocrinol Invest 2020;43:493-503. [PMID: 31705397 DOI: 10.1007/s40618-019-01134-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
9 Younossi ZM, Pham H, Felix S, Stepanova M, Jeffers T, Younossi E, Allawi H, Lam B, Cable R, Afendy M, Younoszai Z, Afendy A, Rafiq N, Alzubaidi N, Ousman Y, Bailey M, Chris Z, Castillo-Catoni M, Fozdar P, Ramirez M, Husain M, Hudson E, Schneider I, Golabi P, Nader F. Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. Clin Transl Gastroenterol 2021;12:e00340. [PMID: 33825721 DOI: 10.14309/ctg.0000000000000340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 López-Islas A, Chagoya-Hazas V, Pérez-Aguilar B, Palestino-Domínguez M, Souza V, Miranda RU, Bucio L, Gómez-Quiroz LE, Gutiérrez-Ruiz MC. Cholesterol Enhances the Toxic Effect of Ethanol and Acetaldehyde in Primary Mouse Hepatocytes. Oxid Med Cell Longev 2016;2016:9209825. [PMID: 26788255 DOI: 10.1155/2016/9209825] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
11 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
12 Lu X, Huang L, Huang Z, Feng D, Clark RJ, Chen C. LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity. Front Endocrinol (Lausanne) 2021;12:717544. [PMID: 34512549 DOI: 10.3389/fendo.2021.717544] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rosato V, Masarone M, Aglitti A, Persico M. The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00018] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Oral A, Sahin T, Turker F, Kocak E. Relationship Between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients. Medicina (Kaunas). 2019;55. [PMID: 31533345 DOI: 10.3390/medicina55090600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
15 Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 28.5] [Reference Citation Analysis]
16 Brea Á, Pintó X, Ascaso JF, Blasco M, Díaz Á, González-Santos P, Hernández Mijares A, Mantilla T, Millán J, Pedro-Botet J; Grupo de trabajo sobre Dislipemia Aterogénica. Sociedad Española de Arteriosclerosis. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease. Clin Investig Arterioscler 2017;29:141-8. [PMID: 27692633 DOI: 10.1016/j.arteri.2016.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Al Attar A, Antaramian A, Noureddin M. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Rev Clin Pharmacol 2021;14:457-64. [PMID: 33612037 DOI: 10.1080/17512433.2021.1894127] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Grander C, Grabherr F, Moschen AR, Tilg H. Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. Visc Med 2016;32:329-34. [PMID: 27921044 DOI: 10.1159/000448940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
19 Manzano-Núñez F, Arámbul-Anthony MJ, Galán Albiñana A, Leal Tassias A, Acosta Umanzor C, Borreda Gascó I, Herrera A, Forteza Vila J, Burks DJ, Noon LA. Insulin resistance disrupts epithelial repair and niche-progenitor Fgf signaling during chronic liver injury. PLoS Biol 2019;17:e2006972. [PMID: 30695023 DOI: 10.1371/journal.pbio.2006972] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
20 Xia F, Zhou BJ. Role of gut-liver axis dysfunction in pathogenesis of non-alcoholic fatty liver disease: Implications for treatment strategies. Shijie Huaren Xiaohua Zazhi 2018; 26(24): 1439-1447 [DOI: 10.11569/wcjd.v26.i24.1439] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Hwangbo H, Kim MY, Ji SY, Kim SY, Lee H, Kim GY, Park C, Keum YS, Hong SH, Cheong J, Choi YH. Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. Antioxidants (Basel) 2020;9:E1040. [PMID: 33114221 DOI: 10.3390/antiox9111040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Byrne CD, Targher G. Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease. Gastroenterology 2016;150:7-10. [DOI: 10.1053/j.gastro.2015.11.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
23 Chenxu G, Minxuan X, Yuting Q, Tingting G, Jing F, Jinxiao L, Sujun W, Yongjie M, Deshuai L, Qiang L, Linfeng H, Xuyuan N, Mingxing W, Ping H, Jun T. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress. Free Radical Biology and Medicine 2019;134:23-41. [DOI: 10.1016/j.freeradbiomed.2018.12.034] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
24 Haghbin H, Gangwani MK, Ravi SJK, Perisetti A, Aziz M, Goyal H, Nawras A, Sodeman T. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Ann Gastroenterol 2020;33:603-14. [PMID: 33162737 DOI: 10.20524/aog.2020.0550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Ren F, Chen Q, Meng C, Chen H, Zhou Y, Zhang H, Chen W. Serum metabonomics revealed the mechanism of Ganoderma amboinense polysaccharides in preventing non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet. Journal of Functional Foods 2021;82:104496. [DOI: 10.1016/j.jff.2021.104496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
26 Singh A, Elboraie A, Lan N, Gupta M. Factors Associated with Deep Vein Thrombosis in Type 2 Diabetics with Biopsy-Proven Non-alcoholic Fatty Liver Disease. SN Compr Clin Med 2020;2:32-41. [DOI: 10.1007/s42399-019-00188-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Liu Q, Li L, Gao L, Li C, Huan Y, Lei L, Cao H, Li L, Gao A, Liu S, Shen Z. Combination of bis (α-furancarboxylato) oxovanadium (IV) and metformin improves hepatic steatosis through down-regulating inflammatory pathways in high-fat diet-induced obese C57BL/6J mice. Basic Clin Pharmacol Toxicol 2021;128:747-57. [PMID: 33599105 DOI: 10.1111/bcpt.13573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Huang X, Chen W, Yan C, Yang R, Chen Q, Xu H, Huang Y. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. Biomedicine & Pharmacotherapy 2019;118:109258. [DOI: 10.1016/j.biopha.2019.109258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
29 Sandeman LY, Kang WX, Wang X, Jensen KB, Wong D, Bo T, Gao L, Zhao J, Byrne CD, Page AJ, Proud CG. Disabling MNK protein kinases promotes oxidative metabolism and protects against diet-induced obesity. Mol Metab 2020;42:101054. [PMID: 32712434 DOI: 10.1016/j.molmet.2020.101054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Li F, Liu G, Xue P, Ren Z, Dai P, Niu W, Xin M. YiQi YangYin Decoction Attenuates Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Rats. Evid Based Complement Alternat Med 2021;2021:5511019. [PMID: 34621322 DOI: 10.1155/2021/5511019] [Reference Citation Analysis]
31 Wang R, Wang Z, Sun R, Fu R, Sun Y, Zhu M, Geng Y, Gao D, Tian X, Zhao Y, Yao J. Activation of TAF9 via Danshensu-Induced Upregulation of HDAC1 Expression Alleviates Non-alcoholic Fatty Liver Disease. Front Pharmacol 2021;12:775528. [PMID: 34925033 DOI: 10.3389/fphar.2021.775528] [Reference Citation Analysis]
32 Arora M, Kutinová Canová N, Farghali H. mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174857] [Reference Citation Analysis]
33 Li J, Li X, Liu D, Zhang S, Tan N, Yokota H, Zhang P. Phosphorylation of eIF2α signaling pathway attenuates obesity-induced non-alcoholic fatty liver disease in an ER stress and autophagy-dependent manner. Cell Death Dis 2020;11:1069. [PMID: 33318479 DOI: 10.1038/s41419-020-03264-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Du F, Huang R, Lin D, Wang Y, Yang X, Huang X, Zheng B, Chen Z, Huang Y, Wang X, Chen F. Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota. Front Microbiol 2021;12:611323. [PMID: 33708180 DOI: 10.3389/fmicb.2021.611323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Federico A, Rosato V, Masarone M, Torre P, Dallio M, Romeo M, Persico M. The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. Nutrients 2021;13:1314. [PMID: 33923525 DOI: 10.3390/nu13041314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Liu T, Xu L, Chen FH, Zhou YB. Association of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol 2020;32:140-7. [PMID: 31895886 DOI: 10.1097/MEG.0000000000001486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Yang Y, Yang X, Lin Y, Yang G, Li L. LASS2 regulates hepatocyte steatosis by interacting with NDUFS2/OXPHOS related proteins. Biochem Biophys Res Commun 2020;526:871-9. [PMID: 32279995 DOI: 10.1016/j.bbrc.2020.02.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Li X, Zeng F, Huang Y, Liu B. The Positive Effects of Grifola frondosa Heteropolysaccharide on NAFLD and Regulation of the Gut Microbiota. Int J Mol Sci 2019;20:E5302. [PMID: 31653116 DOI: 10.3390/ijms20215302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
39 Chen X, Xiao J, Pang J, Chen S, Wang Q, Ling W. Pancreatic β-Cell Dysfunction Is Associated with Nonalcoholic Fatty Liver Disease. Nutrients 2021;13:3139. [PMID: 34579016 DOI: 10.3390/nu13093139] [Reference Citation Analysis]
40 Sahebkar A, Sancho E, Abelló D, Camps J, Joven J. Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review. J Cell Physiol 2018;233:849-55. [PMID: 28063221 DOI: 10.1002/jcp.25779] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
41 Cai Z, Deng X, Jia J, Wang D, Yuan G. Ectodysplasin A/Ectodysplasin A Receptor System and Their Roles in Multiple Diseases. Front Physiol 2021;12:788411. [PMID: 34938205 DOI: 10.3389/fphys.2021.788411] [Reference Citation Analysis]
42 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
43 López-Pastor AR, Infante-Menéndez J, Escribano Ó, Gómez-Hernández A. miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease. Front Med (Lausanne) 2020;7:527059. [PMID: 33102495 DOI: 10.3389/fmed.2020.527059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
44 Cai X, Aierken X, Ahmat A, Cao Y, Zhu Q, Wu T, Li N. A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study. Biomed Res Int 2020;2020:8852198. [PMID: 33204721 DOI: 10.1155/2020/8852198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Schübel R, Nonnenmacher T, Sookthai D, Gonzalez Maldonado S, Sowah SA, von Stackelberg O, Schlett CL, Grafetstätter M, Nabers D, Johnson T, Kirsten R, Ulrich CM, Kaaks R, Kauczor HU, Kühn T, Nattenmüller J. Similar Weight Loss Induces Greater Improvements in Insulin Sensitivity and Liver Function among Individuals with NAFLD Compared to Individuals without NAFLD. Nutrients 2019;11:E544. [PMID: 30836637 DOI: 10.3390/nu11030544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Xiang J, Deng Y, Liu H, Pu Y. LncRNA MALAT1 Promotes PPARα/CD36-Mediated Hepatic Lipogenesis in Nonalcoholic Fatty Liver Disease by Modulating miR-206/ARNT Axis. Front Bioeng Biotechnol 2022;10:858558. [DOI: 10.3389/fbioe.2022.858558] [Reference Citation Analysis]
47 Kumar S, Srivastava A, Palaia T, Hall C, Lee J, Stevenson M, Zhao CL, Ragolia L. Lipocalin-type prostaglandin D2 synthase deletion induces dyslipidemia and non-alcoholic fatty liver disease. Prostaglandins & Other Lipid Mediators 2020;149:106429. [DOI: 10.1016/j.prostaglandins.2020.106429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Kawachi Y, Fujishima Y, Nishizawa H, Nakamura T, Akari S, Murase T, Saito T, Miyazaki Y, Nagao H, Fukuda S, Kita S, Katakami N, Doki Y, Maeda N, Shimomura I. Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation. JCI Insight 2021;6:144762. [PMID: 34494551 DOI: 10.1172/jci.insight.144762] [Reference Citation Analysis]
49 Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019;37:65-72. [PMID: 30705499 DOI: 10.2337/cd18-0026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
50 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
51 Liu W, Zheng KI, Pan X, Ma H, Zhu P, Wu X, Rios RS, Targher G, Byrne CD, Wang X, Chen Y, Zheng M. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2020;35:1057-64. [DOI: 10.1111/jgh.14894] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
52 Anisonyan AV, Sandler YG, Khaimenova TY, Keyan VA, Saliev KG, Sbikina ES, Vinnitskaya EV. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus: issues of the liver fibrosis diagnostics]. Ter Arkh 2020;92:73-8. [PMID: 33346465 DOI: 10.26442/00403660.2020.08.000770] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Chang Y, Ryu S, Sung KC, Cho YK, Sung E, Kim HN, Jung HS, Yun KE, Ahn J, Shin H, Wild SH, Byrne CD. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut 2019;68:1667-75. [PMID: 30472683 DOI: 10.1136/gutjnl-2018-317666] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 21.3] [Reference Citation Analysis]
54 Carrascosa J, Bonanad C, Dauden E, Botella R, Olveira-martín A. Psoriasis e hígado graso no alcohólico. Actas Dermo-Sifiliográficas 2017;108:506-14. [DOI: 10.1016/j.ad.2016.12.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
55 Zhang M, Tang L, Cui X, Yu T, Li Z, Li X, Li G. Shear wave elastography in evaluation of carotid elasticity in the type 2 diabetes mellitus patients with nonalcoholic fatty liver disease. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-022-01097-w] [Reference Citation Analysis]
56 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, Carvalho D, Leite-Moreira A. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413. [PMID: 33010191 DOI: 10.1002/dmrr.3413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
57 Wang H, Li F, Feng J, Wang J, Liu X. The effects of S-nitrosylation-induced PPARγ/SFRP5 pathway inhibition on the conversion of non-alcoholic fatty liver to non-alcoholic steatohepatitis. Ann Transl Med 2021;9:684. [PMID: 33987382 DOI: 10.21037/atm-21-1070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wang K, Li B, Fu R, Jiang Z, Wen X, Ni Y. Bentong ginger oleoresin mitigates liver injury and modulates gut microbiota in mouse with nonalcoholic fatty liver disease induced by high‐fat diet. Journal of Food Science. [DOI: 10.1111/1750-3841.16076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Hsu CS, Kao JH. An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. Expert Rev Gastroenterol Hepatol 2017;11:759-72. [PMID: 28613087 DOI: 10.1080/17474124.2017.1342535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
60 Syväri J, Junker D, Patzelt L, Kappo K, Al Sadat L, Erfanian S, Makowski MR, Hauner H, Karampinos DC. Longitudinal changes on liver proton density fat fraction differ between liver segments. Quant Imaging Med Surg 2021;11:1701-9. [PMID: 33936958 DOI: 10.21037/qims-20-873] [Reference Citation Analysis]
61 Zhang D, Wu S, Lan Y, Chen S, Wang Y, Sun Y, Liao W, Wang L. Blood manganese and nonalcoholic fatty liver disease: A cohort-based case-control study. Chemosphere 2022;287:132316. [PMID: 34592210 DOI: 10.1016/j.chemosphere.2021.132316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Joung H, Kim B, Park H, Lee K, Kim HH, Sim HC, Do HJ, Hyun CK, Do MS. Fermented Moringa oleifera Decreases Hepatic Adiposity and Ameliorates Glucose Intolerance in High-Fat Diet-Induced Obese Mice. J Med Food 2017;20:439-47. [PMID: 28504910 DOI: 10.1089/jmf.2016.3860] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
63 Yang Z, Zhang H, Niu Y, Zhang W, Zhu L, Li X, Lu S, Fan J, Li X, Ning G, Qin L, Su Q. Circulating periostin in relation to insulin resistance and nonalcoholic fatty liver disease among overweight and obese subjects. Sci Rep 2016;6:37886. [PMID: 27885258 DOI: 10.1038/srep37886] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
64 Koo BK, Denenberg JO, Wright CM, Criqui MH, Allison MA. Associations of Perirenal Fat Thickness with Renal and Systemic Calcified Atherosclerosis. Endocrinol Metab (Seoul) 2020;35:122-31. [PMID: 32207272 DOI: 10.3803/EnM.2020.35.1.122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Chen J, Montagner A, Tan NS, Wahli W. Insights into the Role of PPARβ/δ in NAFLD. Int J Mol Sci 2018;19:E1893. [PMID: 29954129 DOI: 10.3390/ijms19071893] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
66 Mikolasevic I, Orlic L, Stimac D, Hrstic I, Jakopcic I, Milic S. Non-alcoholic fatty liver disease and colorectal cancer. Postgrad Med J. 2017;93:153-158. [PMID: 27852946 DOI: 10.1136/postgradmedj-2016-134383] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
67 Ayee MAA, Bunker BC, De Groot JL. Membrane modulatory effects of omega-3 fatty acids: Analysis of molecular level interactions. Curr Top Membr 2020;86:57-81. [PMID: 33837698 DOI: 10.1016/bs.ctm.2020.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Lian J, Fu J. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:615409. [PMID: 33995271 DOI: 10.3389/fendo.2021.615409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Wu L, Liu Y, Zhao Y, Li M, Guo L. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1. Free Radic Biol Med 2020;153:140-58. [PMID: 32311490 DOI: 10.1016/j.freeradbiomed.2020.04.009] [Reference Citation Analysis]
70 Shi T, Wu L, Ma W, Ju L, Bai M, Chen X, Liu S, Yang X, Shi J. Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine. Evid Based Complement Alternat Med 2020;2020:8749564. [PMID: 31998400 DOI: 10.1155/2020/8749564] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
71 Hu C, Zhang Y, Wang S, Lin L, Peng K, Du R, Qi H, Zhang J, Wang T, Zhao Z, Li M, Xu Y, Xu M, Li D, Bi Y, Wang W, Chen Y, Lu J. Association of bedtime with the risk of non‐alcoholic fatty liver disease among middle‐aged and elderly Chinese adults with pre‐diabetes and diabetes. Diabetes Metab Res Rev 2020;36. [DOI: 10.1002/dmrr.3322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Park H, Liu Y, Kim HS, Shin JH. Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease. Nutr Res 2016;36:57-64. [PMID: 26773781 DOI: 10.1016/j.nutres.2015.10.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
73 Reiter FP, Ye L, Ofner A, Schiergens TS, Ziesch A, Brandl L, Ben Khaled N, Hohenester S, Wimmer R, Artmann R, He Y, Lee SML, Mayr D, Zhang C, Gerbes AL, Mayerle J, Denk G, De Toni EN. p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice. Cell Mol Gastroenterol Hepatol 2021;13:95-112. [PMID: 34537439 DOI: 10.1016/j.jcmgh.2021.09.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Fan GH, Wei RL, Wei XY, Zhang CZ, Qi ZT, Xie HY, Zheng SS, Xu X. Key factors and potential drug combinations of nonalcoholic steatohepatitis: Bioinformatic analysis and experimental validation-based study. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00111-9. [PMID: 34233850 DOI: 10.1016/j.hbpd.2021.06.001] [Reference Citation Analysis]
75 Siddiqui B, Kamran M, Tikmani SS, Azmat R, Mushtaq Z, Zafar SB, Khan MT, Yakoob J, Abbas Z. Frequency and risk factors of non-alcoholic fatty liver disease in Helicobacter pylori-infected dyspeptic patients: A cross-sectional study. SAGE Open Med 2021;9:20503121211025421. [PMID: 34211711 DOI: 10.1177/20503121211025421] [Reference Citation Analysis]
76 Sung KC, Lee MY, Lee JY, Lee SH, Kim JY, Wild SH, Byrne CD. Resolution of fatty liver and weight loss: Independent associations with changes in serum lipids and apolipoproteins. Atherosclerosis 2018;272:47-53. [PMID: 29547708 DOI: 10.1016/j.atherosclerosis.2018.03.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
77 Guirguis E, Grace Y, Bolson A, DellaVecchia MJ, Ruble M. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. Pharmacotherapy 2021;41:315-28. [PMID: 33278029 DOI: 10.1002/phar.2489] [Reference Citation Analysis]
78 Chen HJ, Liu J. Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant. Biomed Pharmacother 2018;97:1386-96. [PMID: 29156528 DOI: 10.1016/j.biopha.2017.09.093] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
79 Du J, Ji Y, Qiao L, Liu Y, Lin J. Cellular endo-lysosomal dysfunction in the pathogenesis of non-alcoholic fatty liver disease. Liver Int 2020;40:271-80. [PMID: 31765080 DOI: 10.1111/liv.14311] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
80 Xu F, Guo W. The progress of epigenetics in the development and progression of non-alcoholic fatty liver disease. Liver Research 2020;4:118-23. [DOI: 10.1016/j.livres.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Zhao Q, Wei M, Zhang S, Huang Z, Lu B, Ji L. The water extract of Sophorae tonkinensis Radix et Rhizoma alleviates non-alcoholic fatty liver disease and its mechanism. Phytomedicine 2020;77:153270. [PMID: 32702591 DOI: 10.1016/j.phymed.2020.153270] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Wang X, Zhang Z, Zheng G, Wang A, Sun C, Qin S, Zhuang J, Lu J, Ma D, Zheng Y. Attenuation of hepatic steatosis by purple sweet potato colour is associated with blocking Src/ERK/C/EBPβ signalling in high-fat-diet–treated mice. Appl Physiol Nutr Metab 2017;42:1082-91. [DOI: 10.1139/apnm-2016-0635] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
83 Maseroli E, Comeglio P, Corno C, Cellai I, Filippi S, Mello T, Galli A, Rapizzi E, Presenti L, Truglia MC, Lotti F, Facchiano E, Beltrame B, Lucchese M, Saad F, Rastrelli G, Maggi M, Vignozzi L. Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men. J Endocrinol Invest 2021;44:819-42. [PMID: 32772323 DOI: 10.1007/s40618-020-01381-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
84 Eshraghian A, Nikeghbalian S, Kazemi K, Shamsaeefar A, Geramizadeh B, Malek-Hosseini SA. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB (Oxford) 2020;22:521-8. [PMID: 31431413 DOI: 10.1016/j.hpb.2019.07.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Grgurevic I, Podrug K, Mikolasevic I, Kukla M, Madir A, Tsochatzis EA. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Can J Gastroenterol Hepatol 2020;2020:9181368. [PMID: 32051820 DOI: 10.1155/2020/9181368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
86 Li Y, Sun JP, Wang J, Lu WH, Xie LY, Lv J, Li HX, Yang SF. Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice. Biochem Biophys Res Commun 2019;516:858-65. [PMID: 31266632 DOI: 10.1016/j.bbrc.2019.06.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
87 Liu Y, Dou X, Zhou WY, Ding M, Liu L, Du RQ, Guo L, Qian SW, Tang Y, Yang QQ, Pan DN, Li XY, Lu Y, Cheng JK, Tang QQ. Hepatic Small Ubiquitin-Related Modifier (SUMO)-Specific Protease 2 Controls Systemic Metabolism Through SUMOylation-Dependent Regulation of Liver-Adipose Tissue Crosstalk. Hepatology 2021;74:1864-83. [PMID: 33934381 DOI: 10.1002/hep.31881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
88 Ma Y, Tan Z, Li Q, Fan W, Chen G, Bin Y, Zhou Y, Yi J, Luo X, Tan J, Si Z, Li J. Combined Analysis of Expression Profiles in a Mouse Model and Patients Identified BHMT2 as a New Regulator of Lipid Metabolism in Metabolic-Associated Fatty Liver Disease. Front Cell Dev Biol 2021;9:741710. [PMID: 34869329 DOI: 10.3389/fcell.2021.741710] [Reference Citation Analysis]
89 Chen Y, Huang Q, Ai P, Liu H, Chen X, Xu X, Ding G, Li Y, Feng X, Wang X, Ji L, Li D, Zhou Y. Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease according to Different Menstrual Status Groups. Can J Gastroenterol Hepatol 2019;2019:2763093. [PMID: 31871925 DOI: 10.1155/2019/2763093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
90 Kizivat T, Maric I, Mudri D, Curcic IB, Primorac D, Smolic M. Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications. J Clin Transl Hepatol 2020;8:347-53. [PMID: 33083258 DOI: 10.14218/JCTH.2020.00027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Tsou P, Wu CJ. Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects. J Clin Med 2019;8:E1057. [PMID: 31330971 DOI: 10.3390/jcm8071057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
92 Ezhilarasan D. Advantages and challenges in nanomedicines for chronic liver diseases: A hepatologist's perspectives. Eur J Pharmacol 2021;893:173832. [PMID: 33359144 DOI: 10.1016/j.ejphar.2020.173832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Li Z, Sun F, Hu Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. New-Onset Diabetes Mellitus in Liver Transplant Recipients With Hepatitis C: Analysis of the National Database. Transplantation Proceedings 2016;48:138-44. [DOI: 10.1016/j.transproceed.2015.11.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
94 Yokomori H, Ando W. Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis. BMJ Open Gastroenterol 2020;7:e000370. [PMID: 32414752 DOI: 10.1136/bmjgast-2019-000370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
95 Rebollo-hernanz M, Aguilera Y, Martín-cabrejas MA, Gonzalez de Mejia E. Activating Effects of the Bioactive Compounds From Coffee By-Products on FGF21 Signaling Modulate Hepatic Mitochondrial Bioenergetics and Energy Metabolism in vitro. Front Nutr 2022;9:866233. [DOI: 10.3389/fnut.2022.866233] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Wei YT, Lee PY, Lin CY, Chen HJ, Lin CC, Wu JS, Chang YF, Wu CL, Guo HR. Non-alcoholic fatty liver disease among patients with sleep disorders: a Nationwide study of Taiwan. BMC Gastroenterol 2020;20:32. [PMID: 32041532 DOI: 10.1186/s12876-020-1178-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
98 Sae-Wong J, Chaopathomkul B, Phewplung T, Chaijitraruch N, Sahakitrungruang T. The Prevalence of Nonalcoholic Fatty Liver Disease and Its Risk Factors in Children and Young Adults with Type 1 Diabetes Mellitus. J Pediatr 2021;230:32-37.e1. [PMID: 33250172 DOI: 10.1016/j.jpeds.2020.10.043] [Reference Citation Analysis]
99 Tao G, Zhang G, Chen W, Yang C, Xue Y, Song G, Qin S. A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease. J Cell Mol Med 2022. [PMID: 35734974 DOI: 10.1111/jcmm.17456] [Reference Citation Analysis]
100 Silva MBDBE, Tustumi F, Dantas ACB, Miranda BCJ, Pajecki D, De-cleva R, Santo MA, Nahas SC. OBESIDADE E ESTEATOSE GRAVE: A IMPORTÂNCIA DA AVALIAÇÃO BIOQUÍMICA E ESCORES. ABCD, arq bras cir dig 2021;34:e1626. [DOI: 10.1590/0102-672020210002e1626] [Reference Citation Analysis]
101 Vecera R, Poruba M, Hüttl M, Malinska H, Oliyarnyk O, Markova I, Racova Z, Soukop J, Kazdova L. Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats. CIMB 2022;44:1889-900. [DOI: 10.3390/cimb44050129] [Reference Citation Analysis]
102 Sun Q, Niu Q, Guo Y, Zhuang Y, Li X, Liu J, Li N, Li Z, Huang F, Qiu Z. Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD. J Agric Food Chem 2021;69:8714-25. [PMID: 34323067 DOI: 10.1021/acs.jafc.1c03105] [Reference Citation Analysis]
103 Niu Y, Zhang W, Zhang H, Li X, Lin N, Su W, Gu H, Zhu L, Fan J, Qin L, Yang Z, Su Q. Serum creatinine levels and risk of nonalcohol fatty liver disease in a middle-aged and older Chinese population: A cross-sectional analysis. Diabetes Metab Res Rev 2021;:e3489. [PMID: 34344058 DOI: 10.1002/dmrr.3489] [Reference Citation Analysis]
104 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
105 Singh M, Bittner S, Li Y, Bittner A, Han L, Cortez Y, Inayathullah M, Arif Z, Parthasarathi R, Rajadas J, Shen WJ, Nicolls MR, Kraemer FB, Azhar S. Anti-hyperlipidaemic effects of synthetic analogues of nordihydroguaiaretic acid in dyslipidaemic rats. Br J Pharmacol 2019;176:369-85. [PMID: 30374952 DOI: 10.1111/bph.14528] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
106 Darbandi M, Hamzeh B, Ayenepour A, Rezaeian S, Najafi F, Shakiba E, Pasdar Y. Anti-inflammatory diet consumption reduced fatty liver indices. Sci Rep 2021;11:22601. [PMID: 34799655 DOI: 10.1038/s41598-021-98685-3] [Reference Citation Analysis]
107 Huh JY, Reilly SM, Abu-Odeh M, Murphy AN, Mahata SK, Zhang J, Cho Y, Seo JB, Hung CW, Green CR, Metallo CM, Saltiel AR. TANK-Binding Kinase 1 Regulates the Localization of Acyl-CoA Synthetase ACSL1 to Control Hepatic Fatty Acid Oxidation. Cell Metab 2020;32:1012-1027.e7. [PMID: 33152322 DOI: 10.1016/j.cmet.2020.10.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
108 Ogawa Y, Yoneda M, Kobayashi T, Honda Y, Kessoku T, Imajo K, Saito S, Nakajima A. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2018;20:69-82. [DOI: 10.1080/14656566.2018.1543403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
109 Kim Y, Chang Y, Ryu S, Cho IY, Kwon MJ, Sohn W, Kim MK, Wild SH, Byrne CD. Resolution of, and risk of incident non-alcoholic fatty liver disease with changes in serum 25-hydroxy vitamin D status. J Clin Endocrinol Metab 2022:dgac255. [PMID: 35460237 DOI: 10.1210/clinem/dgac255] [Reference Citation Analysis]
110 Whitson RH Jr, Li SL, Zhang G, Larson GP, Itakura K. Mice with Fabp4-Cre ablation of Arid5b are resistant to diet-induced obesity and hepatic steatosis. Mol Cell Endocrinol 2021;528:111246. [PMID: 33757861 DOI: 10.1016/j.mce.2021.111246] [Reference Citation Analysis]
111 Chung MY, Song JH, Lee J, Shin EJ, Park JH, Lee SH, Hwang JT, Choi HK. Tannic acid, a novel histone acetyltransferase inhibitor, prevents non-alcoholic fatty liver disease both in vivo and in vitro model. Mol Metab 2019;19:34-48. [PMID: 30473486 DOI: 10.1016/j.molmet.2018.11.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
112 Petta S, Ciresi A, Bianco J, Geraci V, Boemi R, Galvano L, Magliozzo F, Merlino G, Craxì A, Giordano C. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One 2017;12:e0186136. [PMID: 29161258 DOI: 10.1371/journal.pone.0186136] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
113 Xiao Z, Chu Y, Qin W. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease. Life Sci 2020;256:117997. [PMID: 32585242 DOI: 10.1016/j.lfs.2020.117997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
114 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 13.4] [Reference Citation Analysis]
115 Makker J, Tariq H, Kumar K, Ravi M, Shaikh DH, Leung V, Hayat U, Hassan MT, Patel H, Nayudu S, Chilimuri S. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. World J Gastroenterol 2021; 27(6): 523-533 [PMID: 33642826 DOI: 10.3748/wjg.v27.i6.523] [Reference Citation Analysis]
116 Sun X, Harris EN. New aspects of hepatic endothelial cells in physiology and nonalcoholic fatty liver disease. Am J Physiol Cell Physiol 2020;318:C1200-13. [PMID: 32374676 DOI: 10.1152/ajpcell.00062.2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
117 Wang X, Li G, Guo C, Zhang J, Kong J, He J, Li F, Liu Y, Yang Y, Lu Z, Liu J. Ethyl 2-[2,3,4-Trimethoxy-6-(1-Octanoyl)Phenyl] Acetate (TMPA) Ameliorates Lipid Accumulation by Disturbing the Combination of LKB1 with Nur77 and Activating the AMPK Pathway in HepG2 Cells and Mice Primary Hepatocytes. Diabetes Metab Syndr Obes 2021;14:4165-77. [PMID: 34629883 DOI: 10.2147/DMSO.S321246] [Reference Citation Analysis]
118 Dua P, Mishra A, Reeta KH. Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection. Biomark Med 2022. [PMID: 35694871 DOI: 10.2217/bmm-2021-1129] [Reference Citation Analysis]
119 de Freitas Diniz TB, de Jesus RN, Jimenez LS, Pareja JC, Chaim EA, Cazzo E. Non-Alcoholic Fatty Liver Disease Is Associated with Impairment of Ejection Fraction Among Individuals with Obesity Undergoing Bariatric Surgery: Results of a Cross-Sectional Study. Obes Surg 2020;30:456-60. [PMID: 31529394 DOI: 10.1007/s11695-019-04179-7] [Reference Citation Analysis]
120 Kim SH, Park HY, Lee HS, Jung KS, Lee MH, Jhee JH, Kim TH, Lee JE, Kim HJ, Kim BS, Park HC, Lee BK, Choi HY. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity. Sci Rep 2020;10:1025. [PMID: 31974458 DOI: 10.1038/s41598-020-57894-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
121 Sung KC, Lee MY, Kim YH, Huh JH, Kim JY, Wild SH, Byrne CD. Obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver. Atherosclerosis 2018;275:50-7. [PMID: 29860108 DOI: 10.1016/j.atherosclerosis.2018.05.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
122 Jeong YH, Hur HJ, Jeon EJ, Park SJ, Hwang JT, Lee AS, Lee KW, Sung MJ. Honokiol Improves Liver Steatosis in Ovariectomized Mice. Molecules 2018;23:E194. [PMID: 29342107 DOI: 10.3390/molecules23010194] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
123 Sinn DH, Cho SJ, Gu S, Seong D, Kang D, Kim H, Yi BK, Paik SW, Guallar E, Cho J, Gwak GY. Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. Gastroenterology. 2016;151:481-488.e1. [PMID: 27283259 DOI: 10.1053/j.gastro.2016.06.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
124 Qiu S, Cao P, Guo Y, Lu H, Hu Y. Exploring the Causality Between Hypothyroidism and Non-alcoholic Fatty Liver: A Mendelian Randomization Study. Front Cell Dev Biol 2021;9:643582. [PMID: 33791302 DOI: 10.3389/fcell.2021.643582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Coilly A, Desterke C, Guettier C, Samuel D, Chiappini F. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Sci Rep 2019;9:19785. [PMID: 31874999 DOI: 10.1038/s41598-019-56235-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
126 Møller S, Kimer N, Barløse M, Bendtsen F. Pathophysiological-based treatments of complications of cirrhosis. Scand J Gastroenterol 2020;55:383-94. [PMID: 32233873 DOI: 10.1080/00365521.2020.1744709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 Carrascosa J, Bonanad C, Dauden E, Botella R, Olveira-martín A. Psoriasis and Nonalcoholic Fatty Liver Disease. Actas Dermo-Sifiliográficas (English Edition) 2017;108:506-14. [DOI: 10.1016/j.adengl.2017.05.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
128 Guo T, Dai Z, You K, Battaglia-Hsu SF, Feng J, Wang F, Li B, Yang J, Li Z. S-adenosylmethionine upregulates the angiotensin receptor-binding protein ATRAP via the methylation of HuR in NAFLD. Cell Death Dis 2021;12:306. [PMID: 33753727 DOI: 10.1038/s41419-021-03591-1] [Reference Citation Analysis]
129 Byrne CD, Newsome PN, Noureddin M. Why are there no Strategies for NAFLD? J Hepatol 2021:S0168-8278(21)02251-0. [PMID: 34933023 DOI: 10.1016/j.jhep.2021.12.009] [Reference Citation Analysis]
130 Ashworth WB, Davies NA, Bogle ID. A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD. PLoS Comput Biol 2016;12:e1005105. [PMID: 27632189 DOI: 10.1371/journal.pcbi.1005105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
131 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
132 Patel HK, Kovacic R, Chandrasekar VT, Patel SC, Singh M, Le Cam E, Burton JH, Ray A, Shah JN. Correlation of Gastrointestinal Symptoms at Initial Presentation with Clinical Outcomes in Hospitalized COVID-19 Patients: Results from a Large Health System in the Southern USA. Dig Dis Sci. [DOI: 10.1007/s10620-022-07384-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Marti-aguado D, Clemente-sanchez A, Bataller R. Cigarette Smoking and Liver Diseases. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.016] [Reference Citation Analysis]
134 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
135 Amanatidou AI, Kaliora AC, Amerikanou C, Stojanoski S, Milosevic N, Vezou C, Beribaka M, Banerjee R, Kalafati IP, Smyrnioudis I, Kurth MJ, Kannt A, Francino MP, Visvikis-Siest S, Deloukas P, Llorens C, Marascio F, Milic N, Medic-Stojanoska M, Gastaldelli A, Trivella MG, Dedoussis GV. Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study. Int J Environ Res Public Health 2022;19:971. [PMID: 35055797 DOI: 10.3390/ijerph19020971] [Reference Citation Analysis]
136 Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res 2020;90:279-89. [PMID: 30789808 DOI: 10.1024/0300-9831/a000528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
137 Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis 2021;20:139. [PMID: 34657611 DOI: 10.1186/s12944-021-01573-y] [Reference Citation Analysis]
138 . Cardiovascular computed tomography and HIV: The evolving role of imaging biomarkers in enhanced risk prediction. Imaging 2021;13:106-18. [DOI: 10.1556/1647.2021.00025] [Reference Citation Analysis]
139 Kwong EK, Zhou H. Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases. Liver Res 2019;3:19-24. [PMID: 31360579 DOI: 10.1016/j.livres.2019.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
140 Tu C, Xiong H, Hu Y, Wang W, Mei G, Wang H, Li Y, Zhou Z, Meng F, Zhang P, Mei Z. Cardiolipin Synthase 1 Ameliorates NASH Through Activating Transcription Factor 3 Transcriptional Inactivation. Hepatology 2020;72:1949-67. [PMID: 32096565 DOI: 10.1002/hep.31202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
141 Li L, Fu J, Liu D, Sun J, Hou Y, Chen C, Shao J, Wang L, Wang X, Zhao R, Wang H, Andersen ME, Zhang Q, Xu Y, Pi J. Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARγ expression. Redox Biol 2020;30:101412. [PMID: 31901728 DOI: 10.1016/j.redox.2019.101412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
142 Tanaka M, Takahashi S, Higashiura Y, Sakai A, Koyama M, Saitoh S, Shimamoto K, Ohnishi H, Furuhashi M. Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. J Diabetes Investig 2021. [PMID: 34889064 DOI: 10.1111/jdi.13735] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Cui Y, Chang R, Zhang T, Zhou X, Wang Q, Gao H, Hou L, Loor JJ, Xu C. Chinese Herbal Formula (CHF03) Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) Through Inhibiting Lipogenesis and Anti-Oxidation Mechanisms. Front Pharmacol 2019;10:1190. [PMID: 31680967 DOI: 10.3389/fphar.2019.01190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
144 Kim NH, Jung YS, Hong HP, Park JH, Kim HJ, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Association between cotinine-verified smoking status and risk of nonalcoholic fatty liver disease. Liver Int 2018;38:1487-94. [DOI: 10.1111/liv.13701] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
145 Idilman IS, Ozdeniz I, Karcaaltincaba M. Hepatic Steatosis: Etiology, Patterns, and Quantification. Seminars in Ultrasound, CT and MRI 2016;37:501-10. [DOI: 10.1053/j.sult.2016.08.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
146 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123-33. [PMID: 28802062 DOI: 10.1002/hep.29466] [Cited by in Crossref: 804] [Cited by in F6Publishing: 699] [Article Influence: 201.0] [Reference Citation Analysis]
147 Khanna S, Parikh NS, VanWagner LB. Fatty liver and cerebrovascular disease: plausible association and possible mechanisms. Curr Opin Lipidol 2022;33:31-8. [PMID: 34799486 DOI: 10.1097/MOL.0000000000000799] [Reference Citation Analysis]
148 El Amrousy D, El Ashry H, Maher S, Ganna S, Hasan S. Pulmonary function test abnormalities in children and adolescents with non-alcoholic fatty liver disease. Eur J Pediatr 2021;180:1693-9. [DOI: 10.1007/s00431-021-03941-3] [Reference Citation Analysis]
149 Hendrikx T, Watzenböck ML, Walenbergh SM, Amir S, Gruber S, Kozma MO, Grabsch HI, Koek GH, Pierik MJ, Staufer K, Trauner M, Kalhan SC, Jonkers D, Hofker MH, Binder CJ, Shiri-Sverdlov R. Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease. BMC Med 2016;14:107. [PMID: 27443391 DOI: 10.1186/s12916-016-0652-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
150 De Munck TJI, Xu P, Vanderfeesten BLJ, Elizalde M, Masclee AAM, Nevens F, Cassiman D, Schaap FG, Jonkers DMAE, Verbeek J. The Role of Brown Adipose Tissue in the Development and Treatment of Nonalcoholic Steatohepatitis: An Exploratory Gene Expression Study in Mice. Horm Metab Res 2020;52:869-76. [PMID: 33260239 DOI: 10.1055/a-1301-2378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Kartoun U. Toward an accelerated adoption of data-driven findings in medicine: Research, skepticism, and the need to speed up public visibility of data-driven findings. Med Health Care and Philos 2019;22:153-7. [DOI: 10.1007/s11019-018-9845-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
152 Pacifico L, Andreoli GM, D’Avanzo M, De Mitri D, Pierimarchi P. Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease. World J Gastroenterol 2018; 24(19): 2073-2082 [PMID: 29785076 DOI: 10.3748/wjg.v24.i19.2073] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
153 Pradhan-Sundd T, Monga SP. Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology. Gene Expr 2019;19:69-87. [PMID: 30646969 DOI: 10.3727/105221619X15469715711907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
154 Wang C, Duan X, Sun X, Liu Z, Sun P, Yang X, Sun H, Liu K, Meng Q. Protective effects of glycyrrhizic acid from edible botanical glycyrrhiza glabra against non-alcoholic steatohepatitis in mice. Food Funct 2016;7:3716-23. [DOI: 10.1039/c6fo00773b] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 3.2] [Reference Citation Analysis]
155 Zhang YY, Li C, Yao GF, Du LJ, Liu Y, Zheng XJ, Yan S, Sun JY, Liu Y, Liu MZ, Zhang X, Wei G, Tong W, Chen X, Wu Y, Sun S, Liu S, Ding Q, Yu Y, Yin H, Duan SZ. Deletion of Macrophage Mineralocorticoid Receptor Protects Hepatic Steatosis and Insulin Resistance Through ERα/HGF/Met Pathway. Diabetes 2017;66:1535-47. [PMID: 28325853 DOI: 10.2337/db16-1354] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
156 Kozaczek M, Bottje W, Albataineh D, Hakkak R. Effects of Short- and Long-Term Soy Protein Feeding on Hepatic Cytochrome P450 Expression in Obese Nonalcoholic Fatty Liver Disease Rat Model. Front Nutr 2021;8:699620. [PMID: 34262928 DOI: 10.3389/fnut.2021.699620] [Reference Citation Analysis]
157 Kantartzis K, Rettig I, Staiger H, Machann J, Schick F, Scheja L, Gastaldelli A, Bugianesi E, Peter A, Schulze M, Fritsche A, Häring H, Stefan N. An extended fatty liver index to predict non-alcoholic fatty liver disease. Diabetes & Metabolism 2017;43:229-39. [DOI: 10.1016/j.diabet.2016.11.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
158 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
159 Wang N, Wang Y, Zhang W, Chen Y, Chen X, Wang C, Li Q, Chen C, Jiang B, Lu Y. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. Diabetes Metab Res Rev 2020;36:e3210. [PMID: 31351021 DOI: 10.1002/dmrr.3210] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
160 Zhuge B, Li G. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator. Biochemical and Biophysical Research Communications 2017;494:687-92. [DOI: 10.1016/j.bbrc.2017.10.149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
161 Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:1388-9. [PMID: 27038241 DOI: 10.1002/hep.28584] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 9.7] [Reference Citation Analysis]
162 Shili-Masmoudi S, Wong GL, Hiriart JB, Liu K, Chermak F, Shu SS, Foucher J, Tse YK, Bernard PH, Yip TC, Merrouche W, Chan HL, Wong VW, de Lédinghen V. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int 2020;40:581-9. [PMID: 31749300 DOI: 10.1111/liv.14301] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
163 Osei TB, van Dijk AM, Dingerink S, Chilunga FP, Beune E, Meeks KAC, Bahendeka S, Schulze MB, Agyemang C, Nicolaou M, Holleboom AG, Danquah I. Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study. Nutrients 2021;13:3679. [PMID: 34835937 DOI: 10.3390/nu13113679] [Reference Citation Analysis]
164 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
165 Zou Y, Zhong L, Hu C, Sheng G. Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids Health Dis 2020;19:245. [PMID: 33239040 DOI: 10.1186/s12944-020-01419-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
166 Rao A, van de Peppel IP, Gumber S, Karpen SJ, Dawson PA. Attenuation of the Hepatoprotective Effects of Ileal Apical Sodium Dependent Bile Acid Transporter (ASBT) Inhibition in Choline-Deficient L-Amino Acid-Defined (CDAA) Diet-Fed Mice. Front Med (Lausanne) 2020;7:60. [PMID: 32158763 DOI: 10.3389/fmed.2020.00060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
167 Ye H, Li Q, Zhang Z, Sun M, Zhao C, Zhang T. Effect of a novel potential probiotic Lactobacillus paracasei Jlus66 isolated from fermented milk on nonalcoholic fatty liver in rats. Food Funct 2017;8:4539-46. [PMID: 29106426 DOI: 10.1039/c7fo01108c] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
168 Milic J, Barbieri S, Gozzi L, Brigo A, Beghé B, Verduri A, Bacca E, Iadisernia V, Cuomo G, Dolci G, Yaacoub D, Aprile E, Belli M, Venuta M, Meschiari M, Sebastiani G, Clini E, Mussini C, Lonardo A, Guaraldi G, Raggi P. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis 2022;9:ofac003. [PMID: 35146047 DOI: 10.1093/ofid/ofac003] [Reference Citation Analysis]
169 Jaruvongvanich V, Chenbhanich J, Sanguankeo A, Rattanawong P, Wijarnpreecha K, Upala S. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:e28-35. [PMID: 28542113 DOI: 10.1097/MEG.0000000000000909] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
170 Cakir M, Akbulut UE, Okten A. Association between Adherence to the Mediterranean Diet and Presence of Nonalcoholic Fatty Liver Disease in Children. Child Obes. 2016;12:279-285. [PMID: 26871614 DOI: 10.1089/chi.2015.0197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
171 Vernuccio F, Cannella R, Bartolotta TV, Galia M, Tang A, Brancatelli G. Advances in liver US, CT, and MRI: moving toward the future. Eur Radiol Exp 2021;5:52. [PMID: 34873633 DOI: 10.1186/s41747-021-00250-0] [Reference Citation Analysis]
172 Xu Y, Ke H, Li Y, Xie L, Su H, Xie J, Mo J, Chen W. Malvidin-3-O-Glucoside from Blueberry Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Transcription Factor EB-Mediated Lysosomal Function and Activating the Nrf2/ARE Signaling Pathway. J Agric Food Chem 2021;69:4663-73. [PMID: 33787249 DOI: 10.1021/acs.jafc.0c06695] [Reference Citation Analysis]
173 Kim KM, Roh JH, Lee S, Yoon JH. Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci Rep 2021;11:2884. [PMID: 33536442 DOI: 10.1038/s41598-021-81959-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
174 Reja D, Makar M, Visaria A, Karanfilian B, Rustgi V. Blood lead level is associated with advanced liver fibrosis in patients with non-alcoholic fatty liver disease: A nationwide survey (NHANES 2011–2016). Annals of Hepatology 2020;19:404-10. [DOI: 10.1016/j.aohep.2020.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 de Mello VD, Matte A, Perfilyev A, Männistö V, Rönn T, Nilsson E, Käkelä P, Ling C, Pihlajamäki J. Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action. Epigenetics 2017;12:287-95. [PMID: 28277977 DOI: 10.1080/15592294.2017.1294305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
176 Shi R, Lin C, Hong Y, Xia X, Chen Y, Li S, Xiu L. Free Triiodothyronine Is Independently Associated with Nonalcoholic Fatty Liver Disease in Hospitalized Type 2 Diabetes Mellitus Patients. Biomed Res Int 2021;2021:8868339. [PMID: 33532498 DOI: 10.1155/2021/8868339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Qiu Z, Zhong D, Yang B. Preventive and Therapeutic Effect of Ganoderma (Lingzhi) on Liver Injury. In: Lin Z, Yang B, editors. Ganoderma and Health. Singapore: Springer; 2019. pp. 217-42. [DOI: 10.1007/978-981-32-9421-9_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
178 Lonardo A, Ballestri S, Targher G. “ Not all forms of NAFLD were created equal ”. Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis? Atherosclerosis 2017;257:253-5. [DOI: 10.1016/j.atherosclerosis.2017.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
179 Li S, Takahara T, Li XK, Fujino M, Sugiyama T, Tsukada K, Liu C, Kakuta Y, Nonomura N, Ito H, Takahashi K, Nakajima M, Tanaka T, Takahara S. 5-Aminolevulinic acid combined with ferrous iron ameliorate ischemia-reperfusion injury in the mouse fatty liver model. Biochem Biophys Res Commun 2016;470:900-6. [PMID: 26820535 DOI: 10.1016/j.bbrc.2016.01.136] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
180 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
181 Um YJ, Chang Y, Jung H, Cho IY, Shin JH, Shin H, Wild SH, Byrne CD, Ryu S. Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. JPM 2022;12:92. [DOI: 10.3390/jpm12010092] [Reference Citation Analysis]
182 Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S, Newsome PN, Oben J, Tomlinson J, Tsochatzis E. Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterol 2017;8:252-9. [PMID: 29067150 DOI: 10.1136/flgastro-2017-100806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
183 Vanessa Fiorentino T, De Vito F, Suraci E, Marasco R, Catalano F, Andreozzi F, Letizia Hribal M, Luzza F, Sesti G. Augmented duodenal levels of sodium/glucose co-transporter 1 are associated with higher risk of nonalcoholic fatty liver disease and noninvasive index of liver fibrosis. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109789] [Reference Citation Analysis]
184 Li Y, Wang J, Tang Y, Han X, Liu B, Hu H, Li X, Yang K, Yuan J, Miao X, Yao P, Wei S, Wang Y, Liang Y, Zhang X, Guo H, Pan A, Yang H, Hu FB, Wu T, He M. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study. PLoS One 2017;12:e0174291. [PMID: 28350839 DOI: 10.1371/journal.pone.0174291] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
185 Sawazaki H, Kitamura Y, Yagi K, Arai Y. Impact of Androgen Deprivation Therapy on Non-Alcoholic Fatty Liver Disease in Patients with Prostate Cancer: A CT Evaluation. Urol Int 2020;104:425-30. [PMID: 32396918 DOI: 10.1159/000507351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
186 Huang S, Mu F, Li F, Wang W, Chen H, Lei L, Ma Y, Ding Y, Wang J. A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease. J Diabetes Res 2020;2020:7867245. [PMID: 32724826 DOI: 10.1155/2020/7867245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
187 Zhang J, Li K, Pan L, Teng F, Zhang P, Lin B, Yuan Y, Wei X, Li W, Zhang H. Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study. BMC Gastroenterol 2021;21:131. [PMID: 33743586 DOI: 10.1186/s12876-021-01721-9] [Reference Citation Analysis]
188 Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front Nutr 2021;8:700058. [PMID: 34250000 DOI: 10.3389/fnut.2021.700058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Katchman H, Zelber-sagi S, Baruch R, Berman G, Schwartz IF, Schwartz D, Nakache R, Goykhman Y, Katz P, Shibolet O, Shashar M, Grupper A. Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controls. Clin Transplant 2018;32:e13240. [DOI: 10.1111/ctr.13240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
190 Lee YJ, Wang CP, Hung WC, Tang WH, Chang YH, Hu DW, Lu YC, Yu TH, Wu CC, Chung FM, Hsu CC. Common and Unique Factors and the Bidirectional Relationship Between Chronic Kidney Disease and Nonalcoholic Fatty Liver in Type 2 Diabetes Patients. Diabetes Metab Syndr Obes 2020;13:1203-14. [PMID: 32368113 DOI: 10.2147/DMSO.S237700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
191 Vitaglione P, Mazzone G, Lembo V, D'Argenio G, Rossi A, Guido M, Savoia M, Salomone F, Mennella I, De Filippis F, Ercolini D, Caporaso N, Morisco F. Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis. J Nutr Sci 2019;8:e15. [PMID: 31037218 DOI: 10.1017/jns.2019.10] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
192 Ye L, Cao Z, Lai X, Shi Y, Zhou N. Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet. J Nutr 2020;150:672-84. [PMID: 31858105 DOI: 10.1093/jn/nxz303] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
193 Baars T, Gieseler RK, Patsalis PC, Canbay A. Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease. Metabolism 2022;:155179. [PMID: 35283187 DOI: 10.1016/j.metabol.2022.155179] [Reference Citation Analysis]
194 Ress C, Kaser S. Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol 2016; 22(4): 1664-1673 [PMID: 26819531 DOI: 10.3748/wjg.v22.i4.1664] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
195 Galarregui C, Marin-Alejandre BA, Perez-Diaz-Del-Campo N, Cantero I, Monreal JI, Elorz M, Benito-Boillos A, Herrero JI, Tur JA, Martínez JA, Zulet MA, Abete I. Predictive Value of Serum Ferritin in Combination with Alanine Aminotransferase and Glucose Levels for Noninvasive Assessment of NAFLD: Fatty Liver in Obesity (FLiO) Study. Diagnostics (Basel) 2020;10:E917. [PMID: 33171699 DOI: 10.3390/diagnostics10110917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Ninić A, Zdravković M, Radosavljević V, Gardijan V, Memon L, Vekić J, Spasojević-kalimanovska V. Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea. Arhiv za farmaciju 2020;70:319-31. [DOI: 10.5937/arhfarm70-27586] [Reference Citation Analysis]
197 Amanatidou AI, Dedoussis GV. Construction and analysis of protein-protein interaction network of non-alcoholic fatty liver disease. Comput Biol Med 2021;131:104243. [PMID: 33550014 DOI: 10.1016/j.compbiomed.2021.104243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
198 Fan J, Chen CJ, Wang YC, Quan W, Wang JW, Zhang WG. Hemodynamic changes in hepatic sinusoids of hepatic steatosis mice. World J Gastroenterol 2019; 25(11): 1355-1365 [PMID: 30918428 DOI: 10.3748/wjg.v25.i11.1355] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
199 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
200 Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 2021;15:206-16. [PMID: 32921636 DOI: 10.5009/gnl20127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
201 Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785-801. [PMID: 32059982 DOI: 10.1016/j.jhep.2020.01.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 28.0] [Reference Citation Analysis]
202 Avignon A. Protecting the Liver: Should We Substitute Fruit Juices for Sugar-Sweetened Beverages? Diabetes Care 2022;45:1032-4. [PMID: 35561135 DOI: 10.2337/dci22-0005] [Reference Citation Analysis]
203 Jang H, Kang D, Chang Y, Kim Y, Lee JS, Kim KW, Jang YK, Kim HJ, Na DL, Shin HY, Kang M, Guallar E, Cho J, Seo SW. Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. Sci Rep 2019;9:1814. [PMID: 30755685 DOI: 10.1038/s41598-018-38357-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
204 Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG, Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Benvengù L, Gasbarrini A, Svegliati Baroni G, Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Metabolic disorders across hepatocellular carcinoma in Italy. Liver Int 2018;38:2028-39. [PMID: 29745475 DOI: 10.1111/liv.13877] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
205 Milic J, Menozzi V, Schepis F, Malagoli A, Besutti G, Franconi I, Raimondi A, Carli F, Mussini C, Sebastiani G, Guaraldi G. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. AIDS 2020;34:1915-21. [PMID: 33009010 DOI: 10.1097/QAD.0000000000002650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
206 Campisano S, La Colla A, Echarte SM, Chisari AN. Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases. Nutr Res Rev 2019;32:128-45. [PMID: 30707092 DOI: 10.1017/S0954422418000239] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
207 Clifford SM, Murphy DJ. Non-alcoholic fatty liver disease and coronary atherosclerosis-does myocardial glucose metabolism provide the missing link? J Nucl Cardiol 2021;28:621-3. [DOI: 10.1007/s12350-019-01783-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
208 El Amrousy D, El Ashry H, Maher S, Ganna S, Hasan S. Pulmonary function test abnormalities in children and adolescents with non-alcoholic fatty liver disease. Eur J Pediatr 2021;180:1693-9. [PMID: 33479799 DOI: 10.1007/s00431-021-03941-3] [Reference Citation Analysis]
209 Sasson A, Kristoferson E, Batista R, McClung JA, Abraham NG, Peterson SJ. The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Arch Biochem Biophys 2021;697:108679. [PMID: 33248947 DOI: 10.1016/j.abb.2020.108679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
210 Wu W, Xiang J, Chen X. Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:773342. [PMID: 34992579 DOI: 10.3389/fendo.2021.773342] [Reference Citation Analysis]
211 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 28.4] [Reference Citation Analysis]
212 Eslam M, Alvani R, Shiha G. Obeticholic acid: towards first approval for NASH. Lancet. 2019;394:2131-2133. [PMID: 31813639 DOI: 10.1016/s0140-6736(19)32963-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
213 Sheng G, Peng N, Hu C, Zhong L, Zhong M, Zou Y. The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population. Lipids Health Dis 2021;20:50. [PMID: 33993872 DOI: 10.1186/s12944-021-01479-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Milroy CM. Fatty Liver and the Forensic Pathologist. Acad Forensic Pathol 2018;8:296-310. [PMID: 31240043 DOI: 10.1177/1925362118782061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
215 Cao X, Gu Y, Bian S, Zhang Q, Meng G, Liu L, Wu H, Zhang S, Wang Y, Zhang T, Wang X, Sun S, Wang X, Jia Q, Song K, Niu K. Association between eating speed and newly diagnosed nonalcoholic fatty liver disease among the general population. Nutr Res 2020;80:78-88. [PMID: 32736293 DOI: 10.1016/j.nutres.2020.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
216 Fallatah HI, Al-Dabbagh A, Hiejazi MT, Hanbazazah SAA, Hussein AO, Al-Sahafi MA, Akbar HO. Prevalence and Clinical Characteristics of NAFLD in Chronic Liver Disease Patients from King Abdulaziz University Hospital, Jeddah. Saudi J Med Med Sci 2020;8:118-24. [PMID: 32587493 DOI: 10.4103/sjmms.sjmms_272_19] [Reference Citation Analysis]
217 Mantovani A, Gatti D, Zoppini G, Lippi G, Bonora E, Byrne CD, Nobili V, Targher G. Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis. Hepatology 2019;70:812-23. [PMID: 30706504 DOI: 10.1002/hep.30538] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
218 Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016; 22(32): 7236-7251 [PMID: 27621571 DOI: 10.3748/wjg.v22.i32.7236] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 98] [Article Influence: 17.7] [Reference Citation Analysis]
219 Qiu T, Pei P, Yao X, Jiang L, Wei S, Wang Z, Bai J, Yang G, Gao N, Yang L, Qi S, Yan R, Liu X, Sun X. Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway. Cell Death Dis 2018;9:946. [PMID: 30237538 DOI: 10.1038/s41419-018-1004-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
220 Houghton D, Zalewski P, Hallsworth K, Cassidy S, Thoma C, Avery L, Slomko J, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, Masson S, Mcpherson S, Anstee QM, Newton JL, Trenell MI. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. Journal of Hepatology 2019;70:1203-13. [DOI: 10.1016/j.jhep.2019.01.035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
221 Zhu K, Tang Y, Xu X, Dang H, Tang LY, Wang X, Wang XW, Zhang YE. Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis. PLoS Biol 2018;16:e3000091. [PMID: 30566427 DOI: 10.1371/journal.pbio.3000091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
222 VanWagner LB, Ning H, Allen NB, Siddique J, Carson AP, Bancks MP, Lewis CE, Carr JJ, Speliotes E, Terrault NA, Rinella ME, Vos MB, Lloyd-Jones DM. Twenty-five-year trajectories of insulin resistance and pancreatic β-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int 2018;38:2069-81. [PMID: 29608255 DOI: 10.1111/liv.13747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
223 Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology 2020;71:1851-64. [PMID: 32012320 DOI: 10.1002/hep.31150] [Cited by in Crossref: 113] [Cited by in F6Publishing: 95] [Article Influence: 56.5] [Reference Citation Analysis]
224 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 329] [Cited by in F6Publishing: 309] [Article Influence: 54.8] [Reference Citation Analysis]
225 Zhou J, Long Y, Ding N, Su Y. Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109195] [Reference Citation Analysis]
226 Liu Y, Xu W, Zhai T, You J, Chen Y. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B 2019;9:745-57. [PMID: 31384535 DOI: 10.1016/j.apsb.2019.02.006] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 16.3] [Reference Citation Analysis]
227 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
228 Hu MJ, Long M, Dai RJ. Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3. Mol Cell Biochem 2021. [PMID: 34652536 DOI: 10.1007/s11010-021-04269-0] [Reference Citation Analysis]
229 Liang Y, Lin C, Huang S, Xu Y. Traditional Chinese Medicine and Intestinal Microbiota: A Complementary and Integrative Health Approach to Ameliorate Obesity-Related Diseases. Holistic Nursing Practice 2019;33:259-65. [DOI: 10.1097/hnp.0000000000000311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
230 Gao Y, Lu J, Liu X, Liu J, Ma Q, Shi Y, Su H. Effect of Long-Term Exercise on Liver Lipid Metabolism in Chinese Patients With NAFLD: A Systematic Review and Meta-Analysis. Front Physiol 2021;12:748517. [PMID: 34880774 DOI: 10.3389/fphys.2021.748517] [Reference Citation Analysis]
231 Xu J, Wang R, You S, Zhang L, Zheng P, Ji G, Liu B. Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial. Trials 2020;21:512. [PMID: 32522273 DOI: 10.1186/s13063-020-04362-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Xue J, Xin H, Ren N, Zhou C, Yang J, Song L, Qin S. Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: A systematic review and meta-analysis. Eur J Clin Invest 2019;49:e13158. [PMID: 31338830 DOI: 10.1111/eci.13158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Chen R, Du J, Zhu H, Ling Q. The role of cGAS-STING signalling in liver diseases. JHEP Rep 2021;3:100324. [PMID: 34381984 DOI: 10.1016/j.jhepr.2021.100324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
234 Song Y, Dang Y, Wang P, Tian G, Ruan L. CHD is Associated With Higher Grades of NAFLD Predicted by Liver Stiffness. J Clin Gastroenterol 2020;54:271-7. [PMID: 31305280 DOI: 10.1097/MCG.0000000000001238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
235 Pan Z, Fan JG, Eslam M. An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. Curr Opin Pharmacol 2021;60:170-6. [PMID: 34455284 DOI: 10.1016/j.coph.2021.07.007] [Reference Citation Analysis]
236 Gong F, Gao L, Ding T. IDH2 protects against nonalcoholic steatohepatitis by alleviating dyslipidemia regulated by oxidative stress. Biochemical and Biophysical Research Communications 2019;514:593-600. [DOI: 10.1016/j.bbrc.2019.04.069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
237 Yu H, Zhao L, Liu L, Li Y, Sun J, Liu Y. Relationship between serum uric acid level and nonalcoholic fatty liver disease in type 2 diabetes patients. Medicine (Baltimore) 2021;100:e26946. [PMID: 34414956 DOI: 10.1097/MD.0000000000026946] [Reference Citation Analysis]
238 Alemany-Pagès M, Moura-Ramos M, Araújo S, Macedo MP, Ribeiro RT, do Ó D, Ramalho-Santos J, Azul AM. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance? BMC Public Health 2020;20:1142. [PMID: 32690054 DOI: 10.1186/s12889-020-09249-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
239 Meroni M, Longo M, Dongiovanni P. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 2020;1:218-43. [DOI: 10.37349/emed.2020.00015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Liu X, Zhou P, He K, Wen Z, Gao Y. Dioscorea Zingiberensis New Saponin Inhibits the Growth of Hepatocellular Carcinoma by Suppressing the Expression of Long Non-coding RNA TCONS-00026762. Front Pharmacol 2021;12:678620. [PMID: 34012402 DOI: 10.3389/fphar.2021.678620] [Reference Citation Analysis]
241 Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of Kidney Dysfunction IN Nafld. CPD 2020;26:1045-61. [DOI: 10.2174/1381612825666191026113119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
242 Song JU, Jang Y, Lim SY, Ryu S, Song WJ, Byrne CD, Sung KC. Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study. PLoS One 2019;14:e0208736. [PMID: 30673698 DOI: 10.1371/journal.pone.0208736] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
243 Qin S, Wang S, Wang X, Wang J. Non-alcoholic fatty liver disease and the risk of urolithiasis: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12092. [PMID: 30170429 DOI: 10.1097/MD.0000000000012092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
244 Wang P, Ji Y, Zhang X, Zhao L, Yan Z, Zhang P, Shen L, Yang X, Fang J, Tian S, Zhu X, Gong J, Zhang X, Wei Q, Wang Y, Li J, Wan L, Xie Q, She Z, Wang Z, Huang Z, Li H. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat Med 2017;23:439-49. [DOI: 10.1038/nm.4290] [Cited by in Crossref: 115] [Cited by in F6Publishing: 119] [Article Influence: 23.0] [Reference Citation Analysis]
245 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Bilson J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020;158:1597-1610. [PMID: 31987796 DOI: 10.1053/j.gastro.2020.01.031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
246 Modares Mousavi SR, Geramizadeh B, Anushiravani A, Ejtehadi F, Anbardar MH, Moini M. Correlation between Serum Ferritin Level and Histopathological Disease Severity in Non-alcoholic Fatty Liver Disease. Middle East J Dig Dis 2018;10:90-5. [PMID: 30013757 DOI: 10.15171/mejdd.2018.96] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
247 Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung S, Gu S, Rhee P, Paik SW, Son HJ, Gwak G. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther 2017;45:345-53. [DOI: 10.1111/apt.13866] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
248 Hong Q, Shen J, Feng Q, Zheng Q, Qiao Y. Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn's disease. BMC Gastroenterol 2022;22:183. [PMID: 35413806 DOI: 10.1186/s12876-022-02238-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Li K, Zhao B, Wei D, Wang W, Cui Y, Qian L, Liu G. miR‑146a improves hepatic lipid and glucose metabolism by targeting MED1. Int J Mol Med 2020;45:543-55. [PMID: 31894315 DOI: 10.3892/ijmm.2019.4443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
250 Liu CQ, He CM, Chen N, Wang D, Shi X, Liu Y, Zeng X, Yan B, Liu S, Yang S, Li X, Li X, Li Z. Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults. Sci Rep. 2016;6:38605. [PMID: 27924915 DOI: 10.1038/srep38605] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
251 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
252 Obayemi MJ, Akintayo CO, Oniyide AA, Aturamu A, Badejogbin OC, Atuma CL, Saidi AO, Mahmud H, Olaniyi KS. Protective role of melatonin against adipose-hepatic metabolic comorbidities in experimentally induced obese rat model. PLoS One 2021;16:e0260546. [PMID: 34879109 DOI: 10.1371/journal.pone.0260546] [Reference Citation Analysis]
253 Pădureanu V, Dop D, Drăgoescu AN, Pădureanu R, Mușetescu AE, Nedelcu L. Non-alcoholic fatty liver disease and hematologic manifestations (Review). Exp Ther Med 2021;22:1355. [PMID: 34659501 DOI: 10.3892/etm.2021.10790] [Reference Citation Analysis]
254 Mantovani A, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A. MAFLD and CKD: An Updated Narrative Review. IJMS 2022;23:7007. [DOI: 10.3390/ijms23137007] [Reference Citation Analysis]
255 An YA, Chen S, Deng Y, Wang ZV, Funcke JB, Shah M, Shan B, Gordillo R, Yoshino J, Klein S, Kusminski CM, Scherer PE. The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. J Hepatol 2021;75:387-99. [PMID: 33746082 DOI: 10.1016/j.jhep.2021.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
256 Chou Y, Sun Z, Shen W, Yang Y, Lu F, Chang C, Li C, Wu J. Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. Front Nutr 2022;9:765206. [DOI: 10.3389/fnut.2022.765206] [Reference Citation Analysis]
257 Tu S, Zhao R, Fang H, Wang L, Shao A, Sheng J. Association between Non-Alcoholic Fatty Liver Disease and Intracerebral Hemorrhage. Cell Transplant 2019;28:1033-8. [PMID: 30922067 DOI: 10.1177/0963689719840025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
258 Hunter H, de Gracia Hahn D, Duret A, Im YR, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, McKeown L, Mitrofan CG, Rao R, Utukuri M, Rowe IA, Mann JP. Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. Elife 2020;9:e56573. [PMID: 33063664 DOI: 10.7554/eLife.56573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Lu P, Yang G, Jiang L, He W, Wu W, Qi L, Shen S, Rao J, Zhang P, Xue Z, Jiang C, Fan G, Zhu X. Characterizing disease progression of nonalcoholic steatohepatitis in Leptin-deficient rats by integrated transcriptome analysis. Exp Biol Med (Maywood) 2021;246:678-87. [PMID: 33302736 DOI: 10.1177/1535370220976530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
260 Jendle J, Hyötyläinen T, Orešič M, Nyström T. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovasc Diabetol 2021;20:237. [PMID: 34920733 DOI: 10.1186/s12933-021-01431-2] [Reference Citation Analysis]
261 Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Cammà C, Porzio M, Rosso C, Fargion S, George J, Craxì A. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver Int 2017;37:1389-96. [PMID: 28235154 DOI: 10.1111/liv.13397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
262 Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, Seong D, Cho SJ, Yi BK, Park HD, Paik SW, Song YB, Lazo M, Lima JA, Guallar E, Cho J, Gwak GY. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 2017;66:323-9. [PMID: 27599521 DOI: 10.1136/gutjnl-2016-311854] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 16.6] [Reference Citation Analysis]
263 Ramadori P, Kam S, Heikenwalder M. T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis. Hepatology 2022;75:1038-49. [PMID: 35023202 DOI: 10.1002/hep.32336] [Reference Citation Analysis]
264 Mann JP, Semple RK, Armstrong MJ. How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease? Front Endocrinol (Lausanne) 2016;7:145. [PMID: 27899914 DOI: 10.3389/fendo.2016.00145] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
265 Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med. 2017;5:270. [PMID: 28758096 DOI: 10.21037/atm.2017.04.41] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
266 Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, Marotta P, Elkhashab M, Bajaj HS, Estes C, Razavi H. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. CMAJ Open 2020;8:E429-36. [PMID: 32518095 DOI: 10.9778/cmajo.20190212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
267 Xia J, Xin L, Zhu W, Li L, Li C, Wang Y, Mu Y, Yang S, Li K. Characterization of long non-coding RNA transcriptome in high-energy diet induced nonalcoholic steatohepatitis minipigs. Sci Rep 2016;6:30709. [PMID: 27466003 DOI: 10.1038/srep30709] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
268 Veracruz N, Hameed B, Saab S, Wong RJ. The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers. J Clin Exp Hepatol 2021;11:45-81. [PMID: 33679048 DOI: 10.1016/j.jceh.2020.04.018] [Reference Citation Analysis]
269 Käräjämäki AJ, Hukkanen J, Kauma H, Kesäniemi YA, Ukkola O. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study). Scand J Clin Lab Invest 2020;80:106-13. [PMID: 31851849 DOI: 10.1080/00365513.2019.1700428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
270 Zhao M, Chen S, Ji X, Shen X, You J, Liang X, Yin H, Zhao L. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacol Res 2021;166:105517. [PMID: 33636349 DOI: 10.1016/j.phrs.2021.105517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Omar N, Koshy M, Hanafiah M, Hatta SFWM, Shah FZM, Johari B, Zamhuri I, Kasim SS, Rahman TA, Ghani RA. Relationships between severity of steatosis with glycemic control and carotid intima-media thickness among diabetic patients with ischemic heart disease. J Res Med Sci 2020;25:64. [PMID: 33088301 DOI: 10.4103/jrms.JRMS_560_17] [Reference Citation Analysis]
272 Sommerfeld O, von Loeffelholz C, Diab M, Kiessling S, Doenst T, Bauer M, Sponholz C. Association between high dose catecholamine support and liver dysfunction following cardiac surgery. J Card Surg 2020;35:1228-36. [PMID: 32333454 DOI: 10.1111/jocs.14555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Wang H, Pai S, Ishiyama S, Guo X, Gao WD, Santhanam L, Gabrielson K, Njoku DB. Mitochondrial-triggered immune responses mechanistically connect drug-induced steatohepatitis and cardiomyopathy associated with nonalcoholic steatohepatitis. Cell Mol Immunol 2021;18:2078-80. [PMID: 34253858 DOI: 10.1038/s41423-021-00724-6] [Reference Citation Analysis]
274 Nagarajan SR, Brandon AE, McKenna JA, Shtein HC, Nguyen TQ, Suryana E, Poronnik P, Cooney GJ, Saunders DN, Hoy AJ. Insulin and diet-induced changes in the ubiquitin-modified proteome of rat liver. PLoS One 2017;12:e0174431. [PMID: 28329008 DOI: 10.1371/journal.pone.0174431] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
275 Chen Y, Chen X, Chen Q, Yu C. Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population. Front Endocrinol (Lausanne) 2021;12:565714. [PMID: 33967948 DOI: 10.3389/fendo.2021.565714] [Reference Citation Analysis]
276 Zhang X, Xu Y, Bai Q, Li X, Han J, Hou Y, Ji Y, Zhang Z. Inhibition of LXR signaling by SULT2B1b promotes liver regeneration after partial hepatectomy in mouse models of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2020;319:G87-96. [PMID: 32475129 DOI: 10.1152/ajpgi.00380.2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
277 Hong Y, Choi SI, Hong E, Kim GH. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice. J Food Sci 2020;85:2216-26. [PMID: 32579753 DOI: 10.1111/1750-3841.15166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
278 Balakrishnan M, Loomba R. The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD. J Clin Gastroenterol 2020;54:107-13. [PMID: 31789757 DOI: 10.1097/MCG.0000000000001284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
279 Yabiku K. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front Endocrinol (Lausanne) 2021;12:768850. [PMID: 34950104 DOI: 10.3389/fendo.2021.768850] [Reference Citation Analysis]
280 Hall RA, Lammert F. Systems Genetics of Liver Fibrosis. In: Schughart K, Williams RW, editors. Systems Genetics. New York: Springer; 2017. pp. 455-66. [DOI: 10.1007/978-1-4939-6427-7_21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
281 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
282 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
283 Zou D, Liu L, Zeng Y, Wang H, Dai D, Xu M. LncRNA MEG3 up-regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease. Cell Death Discov 2022;8:103. [PMID: 35256601 DOI: 10.1038/s41420-022-00889-7] [Reference Citation Analysis]
284 Zou Y, Yu M, Sheng G. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study. Lipids Health Dis 2020;19:145. [PMID: 32563249 DOI: 10.1186/s12944-020-01326-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
285 Fujita T, Daimon M, Mizushiri S, Nishiya Y, Murakami H, Tanabe J, Matsuhashi Y, Yanagimachi M, Tokuda I, Sawada K, Ihara K. FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population. Sci Rep 2020;10:15814. [PMID: 32978491 DOI: 10.1038/s41598-020-72894-8] [Reference Citation Analysis]
286 Rezaei S, Sasani MR, Akhlaghi M, Kohanmoo A. Flaxseed oil in the context of a weight loss programme ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease: a randomised double-blind controlled trial. Br J Nutr 2020;123:994-1002. [DOI: 10.1017/s0007114520000318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
287 Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17:40-52. [PMID: 31641249 DOI: 10.1038/s41575-019-0212-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 22.7] [Reference Citation Analysis]
288 Mikolasevic I, Domislovic V, Filipec Kanizaj T, Radic-Kristo D, Krznaric Z, Milovanovic T, Juric T, Klapan M, Skenderevic N, Delija B, Stevanovic T, Mijic A, Lukic A, Stimac D. Relationship between coffee consumption, sleep duration and smoking status with elastographic parameters of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. Int J Clin Pract 2021;75:e13770. [PMID: 33070425 DOI: 10.1111/ijcp.13770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
289 Fabrizi F, Donato FM, Messa P. Association Between Hepatitis C Virus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Ann Hepatol 2018;17:364-91. [PMID: 29735788 DOI: 10.5604/01.3001.0011.7382] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
290 Liu Y, Liu C, Shi X, Lin M, Yan B, Zeng X, Chen N, Lu S, Liu S, Yang S. Correlations of non-alcoholic fatty liver disease and serum uric acid with subclinical atherosclerosis in obese Chinese adults. J Diabetes. 2016; Jul 1. [Epub ahead of print]. [PMID: 27371101 DOI: 10.1111/1753-0407.12441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
291 Durán-Vian C, Arias-Loste MT, Hernández JL, Fernández V, González M, Iruzubieta P, Rasines L, González-Vela C, Vaqué JP, Blanco R, Crespo J, González-López MA. High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors. J Eur Acad Dermatol Venereol 2019;33:2131-6. [PMID: 31260574 DOI: 10.1111/jdv.15764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
292 Vincent RK, Williams DM, Evans M. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer? Diabetes Obes Metab 2020;22:2227-40. [DOI: 10.1111/dom.14196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
293 Zhang Y, Li J, Liu H. Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-01050-2] [Reference Citation Analysis]
294 Ji L, Cai X, Bai Y, Li T. Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China. Int J Gen Med 2021;14:2909-22. [PMID: 34234521 DOI: 10.2147/IJGM.S319759] [Reference Citation Analysis]
295 Traber MG, Mah E, Leonard SW, Bobe G, Bruno RS. Metabolic syndrome increases dietary α-tocopherol requirements as assessed using urinary and plasma vitamin E catabolites: a double-blind, crossover clinical trial. Am J Clin Nutr 2017;105:571-9. [PMID: 28077381 DOI: 10.3945/ajcn.116.138495] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
296 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
297 [DOI: 10.1101/2020.08.20.20176214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
298 Wang X, Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Front Med (Lausanne) 2021;8:651658. [PMID: 34646834 DOI: 10.3389/fmed.2021.651658] [Reference Citation Analysis]
299 Bellinato F, Goio I, Malara G, Rosato A, Targher G, Girolomoni G, Gisondi P. Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. J Cutan Med Surg 2021;:12034754211066906. [PMID: 34894782 DOI: 10.1177/12034754211066906] [Reference Citation Analysis]
300 Bayoumi A, Grønbæk H, George J, Eslam M. The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends Genet 2020;36:429-41. [PMID: 32396836 DOI: 10.1016/j.tig.2020.03.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
301 Wang Y, Zhu Y, Niu J, Deng Q, Guo S, Jiang H, Peng Z, Xue Y, Peng H, Xuan L, Pan G. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicol Appl Pharmacol 2020;404:115169. [PMID: 32738331 DOI: 10.1016/j.taap.2020.115169] [Reference Citation Analysis]
302 Jung CY, Ryu GW, Kim HW, Ahn SH, Kim SU, Kim BS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia 2021. [PMID: 34932136 DOI: 10.1007/s00125-021-05627-9] [Reference Citation Analysis]
303 Tsuru H, Osaka M, Hiraoka Y, Yoshida M. HFD-induced hepatic lipid accumulation and inflammation are decreased in Factor D deficient mouse. Sci Rep 2020;10:17593. [PMID: 33067533 DOI: 10.1038/s41598-020-74617-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
304 Xu P, Wang S, Pang D. A Novel Identified Peptide Hormone "Metabolitin" Attenuates Lipid Absorption in the Small Intestine of Diabetic Mice with Nonalcoholic Fatty Liver Disease by Regulating Neurotensin and AMPK Signaling Pathway. Evid Based Complement Alternat Med 2021;2021:8386848. [PMID: 34621326 DOI: 10.1155/2021/8386848] [Reference Citation Analysis]
305 Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95:314-322. [PMID: 31085617 DOI: 10.1136/postgradmedj-2018-136316] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
306 Raffaele M, Carota G, Sferrazzo G, Licari M, Barbagallo I, Sorrenti V, Signorelli SS, Vanella L. Inhibition of Heme Oxygenase Antioxidant Activity Exacerbates Hepatic Steatosis and Fibrosis In Vitro. Antioxidants (Basel) 2019;8:E277. [PMID: 31387260 DOI: 10.3390/antiox8080277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
307 Lv Y, Gao X, Luo Y, Fan W, Shen T, Ding C, Yao M, Song S, Yan L. Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways. J Nutr Biochem 2019;71:110-21. [PMID: 31325892 DOI: 10.1016/j.jnutbio.2019.05.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
308 Pirmoazen AM, Khurana A, El Kaffas A, Kamaya A. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics 2020;10:4277-89. [PMID: 32226553 DOI: 10.7150/thno.40249] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 15.5] [Reference Citation Analysis]
309 Saleh Al-Maamari JN, Rahmadi M, Panggono SM, Prameswari DA, Pratiwi ED, Ardianto C, Balan SS, Suprapti B. The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice. J Basic Clin Physiol Pharmacol 2021;32:637-44. [PMID: 34214346 DOI: 10.1515/jbcpp-2020-0423] [Reference Citation Analysis]
310 Zhou F, Zhang Y, Chen J, Hu Y, Xu Y. Verapamil Ameliorates Hepatic Metaflammation by Inhibiting Thioredoxin-Interacting Protein/NLRP3 Pathways. Front Endocrinol (Lausanne) 2018;9:640. [PMID: 30429827 DOI: 10.3389/fendo.2018.00640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
311 Croce AC, Bottiroli G. Lipids: Evergreen autofluorescent biomarkers for the liver functional profiling. Eur J Histochem 2017;61:2808. [PMID: 28735528 DOI: 10.4081/ejh.2017.2808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
312 Mantovani A, Dauriz M, Gatti D, Viapiana O, Zoppini G, Lippi G, Byrne CD, Bonnet F, Bonora E, Targher G. Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. Aliment Pharmacol Ther 2019;49:375-88. [PMID: 30600540 DOI: 10.1111/apt.15087] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
313 Keleidari B, Mahmoudieh M, Gorgi K, Sheikhbahaei E, Shahabi S. Hepatic Failure After Bariatric Surgery: A Systematic Review. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.86078] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
314 Dayton TL, Gocheva V, Miller KM, Israelsen WJ, Bhutkar A, Clish CB, Davidson SM, Luengo A, Bronson RT, Jacks T, Vander Heiden MG. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes Dev 2016;30:1020-33. [PMID: 27125672 DOI: 10.1101/gad.278549.116] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 14.2] [Reference Citation Analysis]
315 Ismaiel A, Popa SL, Dumitrascu DL. Acute Coronary Syndromes and Nonalcoholic Fatty Liver Disease: "Un Affaire de Coeur". Can J Gastroenterol Hepatol 2020;2020:8825615. [PMID: 33313020 DOI: 10.1155/2020/8825615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
316 Targher G. What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. Metabolites. 2020;10. [PMID: 33049948 DOI: 10.3390/metabo10100397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
317 Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol 2018;31:296-304. [PMID: 29720855 DOI: 10.20524/aog.2018.0248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
318 Mantovani A, Zusi C. PNPLA3 gene and kidney disease. Exploration of Medicine 2020;1:42-50. [DOI: 10.37349/emed.2020.00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
319 Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. European Journal of Sport Science 2019;19:994-1003. [DOI: 10.1080/17461391.2019.1571114] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
320 Liu PJ, Lou HP, Zhu YN. Identification of Hepatic Steatosis in Premenopausal and Postmenopausal Women Based on Phenotypes Combining Triglyceride Levels and Anthropometric Indices: A Cross-Sectional Study. Diabetes Metab Syndr Obes 2021;14:1339-47. [PMID: 33790601 DOI: 10.2147/DMSO.S302297] [Reference Citation Analysis]
321 Rinott E, Meir AY, Tsaban G, Zelicha H, Kaplan A, Knights D, Tuohy K, Scholz MU, Koren O, Stampfer MJ, Wang DD, Shai I, Youngster I. The effects of the Green-Mediterranean diet on cardiometabolic health are linked to gut microbiome modifications: a randomized controlled trial. Genome Med 2022;14:29. [PMID: 35264213 DOI: 10.1186/s13073-022-01015-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
322 Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 2021;:1-11. [PMID: 34904923 DOI: 10.1080/14728222.2021.2018418] [Reference Citation Analysis]
323 Corte CD, Iasevoli S, Strologo AD, Sanseviero M, Nobili V. Omega-3 Fatty Acids and Fatty Liver Disease in Children. Adv Food Nutr Res 2018;85:59-77. [PMID: 29860977 DOI: 10.1016/bs.afnr.2018.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
324 Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:430-43. [PMID: 32791578 DOI: 10.3350/cmh.2020.0137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
325 Mcglinchey AJ, Govaere O, Geng D, Ratziu V, Allison M, Bousier J, Petta S, de Oliviera C, Bugianesi E, Schattenberg JM, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. Metabolic signatures across the full spectrum of nonalcoholic fatty liver disease. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100477] [Reference Citation Analysis]
326 Chauhan A, Sultan LR, Furth EE, Jones LP, Khungar V, Sehgal CM. Diagnostic accuracy of hepatorenal index in the detection and grading of hepatic steatosis. J Clin Ultrasound 2016;44:580-6. [PMID: 27447717 DOI: 10.1002/jcu.22382] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
327 Han Y, Zhang Y, Liu S, Chen G, Cao L, Xin Y. Association of LDLR rs1433099 with the Risk of NAFLD and CVD in Chinese Han Population. J Clin Transl Hepatol 2021;9:203-9. [PMID: 34007802 DOI: 10.14218/JCTH.2020.00163] [Reference Citation Analysis]
328 Pahk K, Lee SG, Joung C, Kim EO, Kwon HW, Kim DH, Hwang JI, Kim S, Kim WK. SP-1154, a novel synthetic TGF-β inhibitor, alleviates obesity and hepatic steatosis in high-fat diet-induced mice. Biomed Pharmacother 2022;145:112441. [PMID: 34813997 DOI: 10.1016/j.biopha.2021.112441] [Reference Citation Analysis]
329 Zhang D, Dai J, Zhang M, Xie Y, Cao Y, He G, Xu W, Wang L, Qiao Z, Qiao Z. Paternal nicotine exposure promotes hepatic fibrosis in offspring. Toxicol Lett 2021;343:44-55. [PMID: 33640489 DOI: 10.1016/j.toxlet.2021.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Seko Y, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Mizuno N, Takemura M, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;21:E171. [PMID: 31881781 DOI: 10.3390/ijms21010171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
331 Kim Y, Chang Y, Kwon MJ, Hong YS, Kim MK, Sohn W, Cho YK, Shin H, Wild SH, Byrne CD, Ryu S. Fasting Ketonuria and the Risk of Incident Nonalcoholic Fatty Liver Disease With and Without Liver Fibrosis in Nondiabetic Adults. Am J Gastroenterol 2021. [PMID: 34114568 DOI: 10.14309/ajg.0000000000001344] [Reference Citation Analysis]
332 Moon SW, Kim SY, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Ro JS, Lee YH, Lee SH. Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007-2010. Int J Chron Obstruct Pulmon Dis 2018;13:2603-11. [PMID: 30214178 DOI: 10.2147/COPD.S166902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
333 VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15:75-85. [PMID: 27218012 DOI: 10.1007/s11901-016-0295-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
334 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 171] [Article Influence: 31.0] [Reference Citation Analysis]
335 Ikejima K, Kon K, Yamashina S. Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights. Clin Mol Hepatol 2020;26:728-35. [PMID: 33053942 DOI: 10.3350/cmh.2020.0202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
336 Moraes KCM, Montagne J. Drosophila melanogaster: A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases. Front Physiol 2021;12:728407. [PMID: 34603083 DOI: 10.3389/fphys.2021.728407] [Reference Citation Analysis]
337 Wikan N, Tocharus J, Sivasinprasasn S, Kongkaew A, Chaichompoo W, Suksamrarn A, Tocharus C. Capsaicinoid nonivamide improves nonalcoholic fatty liver disease in rats fed a high-fat diet. J Pharmacol Sci 2020;143:188-98. [PMID: 32414691 DOI: 10.1016/j.jphs.2020.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
338 Ye FZ, Liu WY, Zheng KI, Pan XY, Ma HL, Wang XD, Chen YP, Zheng MH. Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2020;32:80-6. [PMID: 31625959 DOI: 10.1097/MEG.0000000000001483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
339 Gao H, Zhou L, Zhong Y, Ding Z, Lin S, Hou X, Zhou X, Shao J, Yang F, Zou X, Cao H, Xiao G. Kindlin-2 haploinsufficiency protects against fatty liver by targeting Foxo1 in mice. Nat Commun 2022;13:1025. [PMID: 35197460 DOI: 10.1038/s41467-022-28692-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
340 Cui Y, Liu J, Shi H, Hu W, Song L, Zhao Q. Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. J Diabetes Complications 2021;35:107874. [PMID: 33640265 DOI: 10.1016/j.jdiacomp.2021.107874] [Reference Citation Analysis]
341 van Dijk AM, Dingerink S, Chilunga FP, Meeks KAC, Bahendeka S, Schulze MB, Danquah I, Osei TB, Serné E, Agyemang C, Holleboom AG. Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations. J Clin Transl Hepatol 2021;9:494-502. [PMID: 34447678 DOI: 10.14218/JCTH.2021.00066] [Reference Citation Analysis]
342 Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018;68:335-352. [PMID: 29122390 DOI: 10.1016/j.jhep.2017.09.021] [Cited by in Crossref: 224] [Cited by in F6Publishing: 212] [Article Influence: 44.8] [Reference Citation Analysis]
343 Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 2019;39:598-609. [PMID: 30312513 DOI: 10.1111/liv.13986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
344 Geiger MA, Guillaumon AT, Paneni F, Matter CM, Stein S. Role of the Nuclear Receptor Corepressor 1 (NCOR1) in Atherosclerosis and Associated Immunometabolic Diseases. Front Immunol 2020;11:569358. [PMID: 33117357 DOI: 10.3389/fimmu.2020.569358] [Reference Citation Analysis]
345 Frohme J, Tacke F. The socioeconomic aspects of nonalcoholic fatty liver disease: food insecurity as a novel risk factor for steatosis and liver fibrosis. Hepatobiliary Surg Nutr 2020;9:543-5. [PMID: 32832515 DOI: 10.21037/hbsn.2020.03.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
346 Mosca A, Fintini D, Scorletti E, Cappa M, Paone L, Zicari AM, Nobili V, Byrne CD. Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents. Liver Int 2018;38:2301-8. [PMID: 30176114 DOI: 10.1111/liv.13955] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
347 Zhu H, Ge K, Lu J, Jia C. Downregulation of GNAI3 Promotes the Pathogenesis of Methionine/Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease. Gut Liver 2020;14:492-9. [PMID: 31694365 DOI: 10.5009/gnl19115] [Reference Citation Analysis]
348 Tong H, Zhang X, Tan L, Jin R, Huang S, Li X. Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases. Eur J Pharmacol 2020;870:172888. [PMID: 31866404 DOI: 10.1016/j.ejphar.2019.172888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
349 Wang N, Wang Y, Chen X, Zhang W, Chen Y, Xia F, Wan H, Li Q, Jiang B, Hu B, Lu Y. Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes. Front Endocrinol (Lausanne) 2019;10:926. [PMID: 32063885 DOI: 10.3389/fendo.2019.00926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
350 Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? Int J Mol Sci. 2016;17:217. [PMID: 26861300 DOI: 10.3390/ijms17020217] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
351 Popa SL, Ismaiel A, Cristina P, Cristina M, Chiarioni G, David L, Dumitrascu DL. Non-Alcoholic Fatty Liver Disease: Implementing Complete Automated Diagnosis and Staging. A Systematic Review. Diagnostics (Basel) 2021;11:1078. [PMID: 34204822 DOI: 10.3390/diagnostics11061078] [Reference Citation Analysis]
352 Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022;71:778-88. [PMID: 33685968 DOI: 10.1136/gutjnl-2021-324191] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
353 Zhang L, Yao W, Xia J, Wang T, Huang F. Glucagon-Induced Acetylation of Energy-Sensing Factors in Control of Hepatic Metabolism. Int J Mol Sci 2019;20:E1885. [PMID: 30995792 DOI: 10.3390/ijms20081885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
354 Li S, Han S, Jin K, Yu T, Chen H, Zhou X, Tan Z, Zhang G. SOCS2 Suppresses Inflammation and Apoptosis during NASH Progression through Limiting NF-κB Activation in Macrophages. Int J Biol Sci 2021;17:4165-75. [PMID: 34803490 DOI: 10.7150/ijbs.63889] [Reference Citation Analysis]
355 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
356 Wang FX, Zhu N, Zhou F, Lin DX. Natural Aporphine Alkaloids with Potential to Impact Metabolic Syndrome. Molecules 2021;26:6117. [PMID: 34684698 DOI: 10.3390/molecules26206117] [Reference Citation Analysis]
357 Caballeria L, Augustin S, Broquetas T, Morillas RM, Vergara M, Virolés S, Hernández MR, Serra I, Goday A, Vila L, Siso-Almirall A, Solans R, Fernández-Real JM, Carrión JA, Graupera I, Ginès P. Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. Med Clin (Barc) 2019;153:169-77. [PMID: 31178295 DOI: 10.1016/j.medcli.2019.01.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
358 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
359 Atefi M, Entezari MH, Vahedi H, Hassanzadeh A, Laranjo M. Sesame Oil Ameliorates Alanine Aminotransferase, Aspartate Aminotransferase, and Fatty Liver Grade in Women with Nonalcoholic Fatty Liver Disease Undergoing Low-Calorie Diet: A Randomized Double-Blind Controlled Trial. International Journal of Clinical Practice 2022;2022:1-11. [DOI: 10.1155/2022/4982080] [Reference Citation Analysis]
360 Loeffelholz CV, Roth J, Coldewey SM, Birkenfeld AL. The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease. Biomedicines 2021;9:1853. [PMID: 34944668 DOI: 10.3390/biomedicines9121853] [Reference Citation Analysis]
361 Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad F, Kowdley KV, Alkhouri N. Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World J Hepatol 2019; 11(10): 710-718 [PMID: 31749901 DOI: 10.4254/wjh.v11.i10.710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
362 Sargeant JA, Gray LJ, Bodicoat DH, Willis SA, Stensel DJ, Nimmo MA, Aithal GP, King JA. The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis: Exercise, intrahepatic triglyceride and hepatic insulin sensitivity. Obesity Reviews 2018;19:1446-59. [DOI: 10.1111/obr.12719] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
363 Møller S, Bendtsen F. Cardiovascular complications of NAFLD—they do matter. Nat Rev Gastroenterol Hepatol 2015;12:434-6. [DOI: 10.1038/nrgastro.2015.110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
364 Scorletti E, Byrne CD. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. Mol Aspects Med 2018;64:135-46. [PMID: 29544992 DOI: 10.1016/j.mam.2018.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
365 Wójcik K, Piekarska A, Dąbrowicz A, Stasiak M, Gawryś K, Jabłonowska E. Hepatic Expression of Phosphorylated Kinase Akt and Glycogen Synthase Kinase-3 Isoforms in Patients with Chronic Hepatitis C. Viral Immunol 2019;32:179-85. [PMID: 31091179 DOI: 10.1089/vim.2018.0141] [Reference Citation Analysis]
366 Belloni L, Di Cocco S, Guerrieri F, Nunn ADG, Piconese S, Salerno D, Testoni B, Pulito C, Mori F, Pallocca M, Sacconi A, Vivoli E, Marra F, Strano S, Blandino G, Levrero M, Pediconi N. Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. Sci Rep 2018;8:13638. [PMID: 30206377 DOI: 10.1038/s41598-018-31835-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
367 Zhang P, Wang PX, Zhao LP, Zhang X, Ji YX, Zhang XJ, Fang C, Lu YX, Yang X, Gao MM, Zhang Y, Tian S, Zhu XY, Gong J, Ma XL, Li F, Wang Z, Huang Z, She ZG, Li H. The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. Nat Med. 2018;24:84-94. [PMID: 29227477 DOI: 10.1038/nm.4453] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 16.0] [Reference Citation Analysis]
368 Mitrovic M, Sistilli G, Horakova O, Rossmeisl M. Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives. Eur J Clin Invest 2021;:e13650. [PMID: 34291454 DOI: 10.1111/eci.13650] [Reference Citation Analysis]
369 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017;6:62-72. [PMID: 31646122 DOI: 10.1097/XCE.0000000000000126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
370 Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 2021;70:962-9. [PMID: 32938692 DOI: 10.1136/gutjnl-2020-322572] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 84.0] [Reference Citation Analysis]
371 Nobili V, Mantovani A, Cianfarani S, Alisi A, Mosca A, Sartorelli MR, Maffeis C, Loomba R, Byrne CD, Targher G. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. Journal of Hepatology 2019;71:802-10. [DOI: 10.1016/j.jhep.2019.06.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
372 Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018;31:288-295. [PMID: 29720854 DOI: 10.20524/aog.2018.0240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
373 Iruarrizaga-lejarreta M, Arretxe E, Alonso C. Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. Expert Review of Precision Medicine and Drug Development 2019;4:283-97. [DOI: 10.1080/23808993.2019.1685379] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
374 Chou YT, Li CH, Sun ZJ, Shen WC, Yang YC, Lu FH, Chang CJ, Wu JS. A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones. Nutrients 2021;13:914. [PMID: 33799865 DOI: 10.3390/nu13030914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
375 Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936-944. [PMID: 26667191 DOI: 10.1111/jgh.13264] [Cited by in Crossref: 318] [Cited by in F6Publishing: 300] [Article Influence: 63.6] [Reference Citation Analysis]
376 Ge J, Lai JC, Boike JR, German M, Jest N, Morelli G, Spengler E, Said A, Lee A, Hristov A, Desai AP, Junna S, Pokhrel B, Couri T, Paul S, Frenette C, Christian-Miller N, Laurito M, Verna EC, Rahim U, Goel A, Das A, Pine S, Gregory D, VanWagner LB, Kolli KP; Advancing Liver Therapeutic Approaches (ALTA) Study Group. Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post-Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study. Liver Transpl 2021;27:329-40. [PMID: 33217178 DOI: 10.1002/lt.25949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
377 An L, Shi Q, Zhu Y, Wang H, Peng Q, Wu J, Cheng Y, Zhang W, Yi Y, Bao Z, Zhang H, Luo Y, Fan J. Bone morphogenetic protein 4 (BMP4) promotes hepatic glycogen accumulation and reduces glucose level in hepatocytes through mTORC2 signaling pathway. Genes Dis 2021;8:531-44. [PMID: 34179315 DOI: 10.1016/j.gendis.2020.11.004] [Reference Citation Analysis]
378 Xiong Y, Huang J. Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment. Chin Med 2021;16:80. [PMID: 34407830 DOI: 10.1186/s13020-021-00489-0] [Reference Citation Analysis]
379 Wu L, Sun J, Liu L, Du X, Liu Y, Yan X, Kombo Osoro E, Zhang F, Feng L, Liang D, Li Y, Chen Q, Sun S, Zhang L, Lan X, Li D, Lu S. Anti-toll-like receptor 2 antibody ameliorates hepatic injury, inflammation, fibrosis and steatosis in obesity-related metabolic disorder rats via regulating MAPK and NF-κB pathways. Int Immunopharmacol 2020;82:106368. [PMID: 32151955 DOI: 10.1016/j.intimp.2020.106368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
380 Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016;17. [PMID: 27231906 DOI: 10.3390/ijms17060803] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
381 Stöckli J, Zadoorian A, Cooke KC, Deshpande V, Yau B, Herrmann G, Kebede MA, Humphrey SJ, James DE. ABHD15 regulates adipose tissue lipolysis and hepatic lipid accumulation. Mol Metab 2019;25:83-94. [PMID: 31105056 DOI: 10.1016/j.molmet.2019.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
382 Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martinez JA, Zulet MA. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Nutrients 2019;11:E2543. [PMID: 31652512 DOI: 10.3390/nu11102543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
383 Ren TY, Li XY, Fan JG. Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try. Clin Mol Hepatol 2021;27:83-6. [PMID: 33317240 DOI: 10.3350/cmh.2020.0298] [Reference Citation Analysis]
384 Hörist-kollmann S, Strametz-juranek J. Female Dietary Patterns and the Pathogenesis of NAFLD. Gender and the Genome 2018;2:49-55. [DOI: 10.1177/2470289718787091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
385 Kwak M, Yim JY, Yi A, Chung G, Yang JI, Kim D, Kim JS, Noh D. Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women. Digestive and Liver Disease 2019;51:1030-5. [DOI: 10.1016/j.dld.2018.12.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
386 Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, Huh W, Paik SW, Ryu S, Chang Y, Shafi T, Lazo M, Guallar E, Cho J, Gwak GY. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018;8:4718. [PMID: 29549269 DOI: 10.1038/s41598-018-23014-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
387 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Reference Citation Analysis]
388 Li J, Li T. Bile acid receptors link nutrient sensing to metabolic regulation. Liver Res 2017;1:17-25. [PMID: 29098111 DOI: 10.1016/j.livres.2017.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
389 Duseja A, Najmy S, Sachdev S, Pal A, Sharma RR, Marwah N, Chawla Y. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open 2019;3:133-9. [PMID: 31061888 DOI: 10.1002/jgh3.12117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
390 Li Z, Feng S, Zhou L, Liu S, Cheng J. NS5ATP6 modulates intracellular triglyceride content through FGF21 and independently of SIRT1 and SREBP1. Biochem Biophys Res Commun 2016;475:133-9. [PMID: 27179781 DOI: 10.1016/j.bbrc.2016.05.056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
391 Collin de l'Hortet A, Takeishi K, Guzman-Lepe J, Morita K, Achreja A, Popovic B, Wang Y, Handa K, Mittal A, Meurs N, Zhu Z, Weinberg F, Salomon M, Fox IJ, Deng CX, Nagrath D, Soto-Gutierrez A. Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. Cell Metab 2019;30:385-401.e9. [PMID: 31390551 DOI: 10.1016/j.cmet.2019.06.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
392 Sánchez V, Brandt A, Jin CJ, Rajcic D, Engstler AJ, Jung F, Nier A, Baumann A, Bergheim I. Fortifying Butterfat with Soybean Oil Attenuates the Onset of Diet-Induced Non-Alcoholic Steatohepatitis and Glucose Intolerance. Nutrients 2021;13:959. [PMID: 33809593 DOI: 10.3390/nu13030959] [Reference Citation Analysis]
393 von Loeffelholz C, Coldewey SM, Birkenfeld AL. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells 2021;10:1822. [PMID: 34359991 DOI: 10.3390/cells10071822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
394 Bugianesi E. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action? Diabetologia 2016;59:1145-7. [DOI: 10.1007/s00125-016-3930-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
395 Khoo NKH, Fazzari M, Chartoumpekis DV, Li L, Guimaraes DA, Arteel GE, Shiva S, Freeman BA. Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis. Redox Biol 2019;22:101132. [PMID: 30769284 DOI: 10.1016/j.redox.2019.101132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
396 Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther 2015;9:4835-45. [PMID: 26316717 DOI: 10.2147/DDDT.S64877] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
397 Gong H, Liu X, Cheng F. Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. J Int Med Res 2021;49:3000605211047074. [PMID: 34590877 DOI: 10.1177/03000605211047074] [Reference Citation Analysis]
398 Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-peralta F. Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. JCM 2022;11:968. [DOI: 10.3390/jcm11040968] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
399 Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z, Zhou L, Xie H, Zheng S. Metabolic Changes of Hepatocytes in NAFLD. Front Physiol 2021;12:710420. [PMID: 34526911 DOI: 10.3389/fphys.2021.710420] [Reference Citation Analysis]
400 Jamali R, Pourhassan S, Maghbouli N, Ashraf H, Sohrabpour AA. Liver fat content might be an appropriate measure for estimation of cardiovascular disease risk in non-alcoholic steatohepatitis patients. Med J Islam Repub Iran. 2020;34:135. [PMID: 33437731 DOI: 10.34171/mjiri.34.135] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
401 Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, Liu X, Li C, Chen S, Ye J, Huang Z, Lu Y. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes 2021;13:1-19. [PMID: 34030573 DOI: 10.1080/19490976.2021.1927633] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
402 Harvie R, Walmsley R, Schultz M; New Zealand Society of Gastroenterology. "We are what our bacteria eat": The role of bacteria in personalizing nutrition therapy in gastrointestinal conditions. J Gastroenterol Hepatol 2017;32:352-7. [PMID: 27248703 DOI: 10.1111/jgh.13462] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
403 Igarashi H, Shigiyama F, Wakui N, Nagai H, Shibuya K, Shiraga N, Hirose T, Kumashiro N. Whole hepatic lipid volume quantification and color mapping by multi-slice and multi-point magnetic resonance imaging. Hepatol Res 2019;49:1374-85. [PMID: 31313870 DOI: 10.1111/hepr.13408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
404 Zhang N, Tao J, Gao L, Bi Y, Li P, Wang H, Zhu D, Feng W. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet. Biomed Res Int 2020;2020:2947549. [PMID: 32149099 DOI: 10.1155/2020/2947549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
405 Bae JC, Han JM, Cho JH, Kwon H, Park SE, Park CY, Lee WY, Oh KW, Kwon S, Park SW, Rhee EJ. The persistence of fatty liver has a differential impact on the development of diabetes: The Kangbuk Samsung Health Study. Diabetes Res Clin Pract 2018;135:1-6. [PMID: 29111276 DOI: 10.1016/j.diabres.2017.10.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
406 Hodges JK, Sasaki GY, Bruno RS. Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies. J Nutr Biochem 2020;85:108478. [PMID: 32801031 DOI: 10.1016/j.jnutbio.2020.108478] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
407 Schafberg M, Loest K, Müller-Belecke A, Rohn S. Pike-Perch (Sander lucioperca) and Rainbow Trout (Oncorhynchus mykiss) Fed with an Alternative Microorganism Mix for Reducing Fish Meal and Oil-Fishes' Growth Performances and Quality Traits. Foods 2021;10:1799. [PMID: 34441576 DOI: 10.3390/foods10081799] [Reference Citation Analysis]
408 Kwon HC, Song JJ, Park YB, Lee SW. Fibrosis-5 predicts end-stage renal disease in patients with microscopic polyangiitis and granulomatosis with polyangiitis without substantial liver diseases. Clin Exp Med 2021;21:399-406. [PMID: 33611672 DOI: 10.1007/s10238-021-00691-2] [Reference Citation Analysis]
409 Han L, Shen WJ, Bittner S, Kraemer FB, Azhar S. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. Future Cardiol 2017;13:279-96. [PMID: 28581362 DOI: 10.2217/fca-2017-0019] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 14.2] [Reference Citation Analysis]
410 Shaunak M, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Non-alcoholic fatty liver disease and childhood obesity.Arch Dis Child. 2021;106:3-8. [PMID: 32409495 DOI: 10.1136/archdischild-2019-318063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
411 Schwarzkopf K, Bojunga J, Rüschenbaum S, Martinez Y, Mücke MM, Seeger F, Schoelzel F, Zeuzem S, Friedrich-Rust M, Lange CM. Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease. Hepatol Commun 2018;2:1601-9. [PMID: 30556044 DOI: 10.1002/hep4.1254] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
412 Byrne CD, Perseghin G. Non-alcoholic fatty liver disease: A risk factor for myocardial dysfunction? Journal of Hepatology 2018;68:640-2. [DOI: 10.1016/j.jhep.2017.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
413 Wang M, Li B, Qin F, Ye J, Jin L. Obesity induced Ext1 reduction mediates the occurrence of NAFLD. Biochem Biophys Res Commun 2021;589:123-30. [PMID: 34906902 DOI: 10.1016/j.bbrc.2021.12.017] [Reference Citation Analysis]
414 Tang X, Shi Y, Du J, Hu K, Zhou T, Chen L, Zhang Y, Li F, Zhang H, Liebe R, Meyer C, Dooley S, Zhu Z, Weng HL, Jia J, Huang T. Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study. BMJ Open 2022;12:e054891. [PMID: 35760549 DOI: 10.1136/bmjopen-2021-054891] [Reference Citation Analysis]
415 Khoo WY, Chrisfield BJ, Sae-Tan S, Lambert JD. Mitigation of nonalcoholic fatty liver disease in high-fat-fed mice by the combination of decaffeinated green tea extract and voluntary exercise. J Nutr Biochem 2020;76:108262. [PMID: 31759197 DOI: 10.1016/j.jnutbio.2019.108262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
416 Rubio C, Puerto M, García-Rodríquez JJ, Lu VB, García-Martínez I, Alén R, Sanmartín-Salinas P, Toledo-Lobo MV, Saiz J, Ruperez J, Barbas C, Menchén L, Gribble FM, Reimann F, Guijarro LG, Carrascosa JM, Valverde ÁM. Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice. Mol Metab 2020;35:100954. [PMID: 32244182 DOI: 10.1016/j.molmet.2020.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Sbeit W, Greener T, Kadah A, Mari A, Goldin E, Khoury T, Mahamid M. Pancreatobiliary manifestations of nonalcoholic fatty liver disease: a retrospective case-control multicenter study. Eur J Gastroenterol Hepatol 2021;33:722-6. [PMID: 32483086 DOI: 10.1097/MEG.0000000000001780] [Reference Citation Analysis]
418 Zang S, Chen J, Song Y, Bai L, Chen J, Chi X, He F, Sheng H, Wang J, Xie S, Xie W, Yang Y, Zhang J, Zheng M, Zou Z, Wang B, Shi J; Chinese NAFLD Clinical Research Network (CNAFLD CRN). Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. Adv Ther 2018;35:218-31. [PMID: 29411270 DOI: 10.1007/s12325-018-0670-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
419 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
420 Longo M, Meroni M, Paolini E, Erconi V, Carli F, Fortunato F, Ronchi D, Piciotti R, Sabatini S, Macchi C, Alisi A, Miele L, Soardo G, Comi GP, Valenti L, Ruscica M, Fracanzani AL, Gastaldelli A, Dongiovanni P. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00241-1. [PMID: 34823063 DOI: 10.1016/j.jcmgh.2021.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
421 Noda T, Kamiya K, Hamazaki N, Nozaki K, Ichikawa T, Yamashita M, Uchida S, Maekawa E, Terada T, Reed JL, Yamaoka-tojo M, Matsunaga A, Ako J. The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome. JCM 2022;11:1847. [DOI: 10.3390/jcm11071847] [Reference Citation Analysis]
422 Desterke C, Chiappini F. Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway. Int J Mol Sci 2019;20:E5594. [PMID: 31717414 DOI: 10.3390/ijms20225594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
423 Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2015;1852:1765-78. [DOI: 10.1016/j.bbadis.2015.05.015] [Cited by in Crossref: 127] [Cited by in F6Publishing: 134] [Article Influence: 18.1] [Reference Citation Analysis]
424 Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network?J Dtsch Dermatol Ges. 2021;19:517-528. [PMID: 33768700 DOI: 10.1111/ddg.14425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
425 Ehsani S, Zolfaghari H, Kazemi S, Shidfar F. Effects of sumac (Rhus coriaria) on lipid profile, leptin and steatosis in patients with non-alcoholic fatty liver disease: A randomized double-blind placebo-controlled trial. Journal of Herbal Medicine 2022;31:100525. [DOI: 10.1016/j.hermed.2021.100525] [Reference Citation Analysis]
426 Kim G, Lee HC, Choe J, Kim M, Lee MJ, Chang H, Bae IY, Kim H, An J, Shim JH, Kim KM, Lim Y. Association between non-alcoholic fatty liver disease and cancer incidence rate. Journal of Hepatology 2018;68:140-6. [DOI: 10.1016/j.jhep.2017.09.012] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 15.3] [Reference Citation Analysis]
427 Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM. Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. Hepatol Commun 2020;4:1136-48. [PMID: 32766474 DOI: 10.1002/hep4.1534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
428 Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, McGurnaghan S, McCrimmon R, Read SH, Sattar N, Byrne CD; Scottish Diabetes Research Network Epidemiology Group. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care 2018;41:341-7. [PMID: 29167212 DOI: 10.2337/dc17-1590] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 14.0] [Reference Citation Analysis]
429 Weinstein AA, De Avila L, Kannan S, Paik JM, Golabi P, Gerber LH, Younossi ZM. Interrelationship between physical activity and depression in nonalcoholic fatty liver disease. World J Hepatol 2022; 14(3): 612-622 [DOI: 10.4254/wjh.v14.i3.612] [Reference Citation Analysis]
430 Vural H, Armutcu F, Akyol O, Weiskirchen R. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases. Clin Chim Acta 2021;523:374-9. [PMID: 34678296 DOI: 10.1016/j.cca.2021.10.018] [Reference Citation Analysis]
431 Wahlström A. Outside the liver box: The gut microbiota as pivotal modulator of liver diseases. Biochim Biophys Acta Mol Basis Dis 2019;1865:912-9. [PMID: 31007175 DOI: 10.1016/j.bbadis.2018.07.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
432 Wen WX, Lee SY, Siang R, Koh RY. Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. Adv Ther 2017;34:1245-69. [PMID: 28484954 DOI: 10.1007/s12325-017-0547-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
433 Khiatah B, Nasrollah L, Covington S, Carlson D. Nonalcoholic fatty liver disease as a risk factor for cytomegalovirus hepatitis in an immunocompetent patient: A case report. World J Clin Cases 2021; 9(6): 1455-1460 [PMID: 33644215 DOI: 10.12998/wjcc.v9.i6.1455] [Reference Citation Analysis]
434 Yoshida R, Yano Y, Hoshi N, Okamoto N, Sui Y, Yamamoto A, Asaji N, Shiomi Y, Yasutomi E, Hatazawa Y, Hayashi H, Ueda Y, Kodama Y. Acid-treated high-amylose corn starch suppresses high-fat diet-induced steatosis. J Food Sci 2022. [PMID: 35411589 DOI: 10.1111/1750-3841.16146] [Reference Citation Analysis]
435 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
436 Ismaiel A, Spinu M, Budisan L, Leucuta DC, Popa SL, Chis BA, Berindan-Neagoe I, Olinic DM, Dumitrascu DL. Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease. J Clin Med 2021;10:5194. [PMID: 34768714 DOI: 10.3390/jcm10215194] [Reference Citation Analysis]
437 Murillo AG, DiMarco DM, Fernandez ML. The Potential of Non-Provitamin A Carotenoids for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease. Biology (Basel). 2016;5. [PMID: 27834813 DOI: 10.3390/biology5040042] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
438 Skinner RC, Hagaman JA. The interplay of Western diet and binge drinking on the onset, progression, and outlook of liver disease. Nutr Rev 2021:nuab031. [PMID: 33969426 DOI: 10.1093/nutrit/nuab031] [Reference Citation Analysis]
439 Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 2022;22:63. [PMID: 35287643 DOI: 10.1186/s12902-022-00980-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
440 Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin Exp Med 2022. [PMID: 35192111 DOI: 10.1007/s10238-022-00799-z] [Reference Citation Analysis]
441 Dogru T, Kirik A, Gurel H, Rizvi AA, Rizzo M, Sonmez A. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int J Mol Sci 2021;22:6627. [PMID: 34205674 DOI: 10.3390/ijms22126627] [Reference Citation Analysis]
442 Li F, Sun G, Wang Z, Wu W, Guo H, Peng L, Wu L, Guo X, Yang Y. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. Sci China Life Sci 2018;61:770-8. [PMID: 29948900 DOI: 10.1007/s11427-017-9303-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
443 Hu YY, Dong NL, Qu Q, Zhao XF, Yang HJ. The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients. Medicine (Baltimore) 2018;97:e12931. [PMID: 30412101 DOI: 10.1097/MD.0000000000012931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
444 Sung KC, Ryu S, Lee JY, Kim JY, Wild SH, Byrne CD. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol 2016;65:791-7. [PMID: 27255583 DOI: 10.1016/j.jhep.2016.05.026] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 10.0] [Reference Citation Analysis]
445 Bima A, Eldakhakhny B, Nuwaylati D, Alnami A, Ajabnoor M, Elsamanoudy A. The Interplay of Vitamin D Deficiency and Cellular Senescence in The Pathogenesis of Obesity-Related Co-Morbidities. Nutrients 2021;13:4127. [PMID: 34836382 DOI: 10.3390/nu13114127] [Reference Citation Analysis]
446 Dobrindt EM, Allex L, Saipbaev A, Öllinger R, Schöning W, Pratschke J, Eurich D. Association between obesity after liver transplantation and steatosis, inflammation, and fibrosis of the graft. Clin Transplant 2020;34:e14093. [PMID: 32970896 DOI: 10.1111/ctr.14093] [Reference Citation Analysis]
447 Gong X, Li T, Wan R, Sha L. Cordycepin attenuates high-fat diet-induced non-alcoholic fatty liver disease via down-regulation of lipid metabolism and inflammatory responses. Int Immunopharmacol 2021;91:107173. [PMID: 33352441 DOI: 10.1016/j.intimp.2020.107173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
448 Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Liver Int. 2020;40:1254-1261. [PMID: 32301554 DOI: 10.1111/liv.14478] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 35.5] [Reference Citation Analysis]
449 Xie Y, Tian H, Xiang B, Li D, Liu J, Cai Z, Liu Y, Xiang H. Total polyunsaturated fatty acid intake and the risk of non-alcoholic fatty liver disease in Chinese Han adults: a secondary analysis based on a case-control study. BMC Gastroenterol 2021;21:451. [PMID: 34847883 DOI: 10.1186/s12876-021-02039-2] [Reference Citation Analysis]
450 You N, Xu J, Wang L, Zhuo L, Zhou J, Song Y, Ali A, Luo Y, Yang J, Yang W, Zheng M, Xu J, Shao L, Shi J. Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. Obesity (Silver Spring) 2021;29:350-8. [PMID: 33491316 DOI: 10.1002/oby.23073] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
451 Laitinen TT, Vahtera J, Pahkala K, Magnussen CG, Nuotio J, Hutri-Kähönen N, Kivimäki M, Lehtimäki T, Jokinen E, Laitinen T, Tossavainen P, Pentti J, Viikari JSA, Juonala M, Raitakari OT. Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study. Hepatology 2020;71:67-75. [PMID: 31169929 DOI: 10.1002/hep.30804] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
452 Chu Q, Zhang S, Chen M, Han W, Jia R, Chen W, Zheng X. Cherry Anthocyanins Regulate NAFLD by Promoting Autophagy Pathway. Oxid Med Cell Longev 2019;2019:4825949. [PMID: 30931080 DOI: 10.1155/2019/4825949] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
453 Wang K, Tan W, Liu X, Deng L, Huang L, Wang X, Gao X. New insight and potential therapy for NAFLD: CYP2E1 and flavonoids. Biomed Pharmacother 2021;137:111326. [PMID: 33556870 DOI: 10.1016/j.biopha.2021.111326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
454 Mollica G, Senesi P, Codella R, Vacante F, Montesano A, Luzi L, Terruzzi I. L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. Dig Liver Dis 2020;52:314-23. [PMID: 31607566 DOI: 10.1016/j.dld.2019.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
455 Zheng X, Cao C, He Y, Wang X, Wu J, Hu H. Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching. Lipids Health Dis 2021;20:59. [PMID: 34130693 DOI: 10.1186/s12944-021-01485-x] [Reference Citation Analysis]
456 Ayaz T, Polat HB, Kilictas B. Evaluation of the reciprocal interaction between hepatic steatosis and type 2 diabetes: a comparative analysis with respect to anti-diabetic treatment, glycemic control, renal and hepatic function. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-021-01009-4] [Reference Citation Analysis]
457 Kovacovicova K, Vinciguerra M. Inhibition of dipeptidyl peptidase 4 (DPP4) activates immune cells chemotaxis in hepatocellular carcinoma. Oncology Signaling 2019;2:1-3. [DOI: 10.1016/j.onsig.2019.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
458 Wang Y, Ding WX, Li T. Cholesterol and bile acid-mediated regulation of autophagy in fatty liver diseases and atherosclerosis. Biochim Biophys Acta Mol Cell Biol Lipids 2018;1863:726-33. [PMID: 29653253 DOI: 10.1016/j.bbalip.2018.04.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
459 Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A. Nicht-alkoholische Fettlebererkrankung und Psoriasis - besteht ein gemeinsames proinflammatorisches Netzwerk? J Dtsch Dermatol Ges 2021;19:517-29. [PMID: 33861000 DOI: 10.1111/ddg.14425_g] [Reference Citation Analysis]
460 Lee J, Kim HS, Cho YK, Kim EH, Lee MJ, Bae IY, Jung CH, Park JY, Kim HK, Lee WJ. Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease. Sci Rep 2020;10:18323. [PMID: 33110139 DOI: 10.1038/s41598-020-75266-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
461 Wójcik-Cichy K, Koślińska-Berkan E, Piekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp Hepatol 2018;4:1-6. [PMID: 29594192 DOI: 10.5114/ceh.2018.73155] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
462 Wu JT, He BW, Cao JL, Yan JB, Chen ZY. Involvement of STING signaling pathway in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(24): 1396-1401 [DOI: 10.11569/wcjd.v29.i24.1396] [Reference Citation Analysis]
463 Musaogullari A, Chai YC. Redox Regulation by Protein S-Glutathionylation: From Molecular Mechanisms to Implications in Health and Disease. Int J Mol Sci 2020;21:E8113. [PMID: 33143095 DOI: 10.3390/ijms21218113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
464 Chen H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. Liver Research 2020;4:15-22. [DOI: 10.1016/j.livres.2020.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
465 Wijarnpreecha K, Panjawatanan P, Thongprayoon C, Jaruvongvanich V, Ungprasert P. Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol 2017;23:311-7. [PMID: 29205182 DOI: 10.4103/sjg.SJG_161_17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
466 Fan M, Choi YJ, Tang Y, Bae SM, Yang HP, Kim EK. Efficacy and Mechanism of Polymerized Anthocyanin from Grape-Skin Extract on High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease. Nutrients 2019;11:E2586. [PMID: 31717842 DOI: 10.3390/nu11112586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
467 Wang J, Zheng D, Huang F, Zhao A, Kuang J, Ren Z, Chen T, Lei J, Lin J, Wang X, Jia W, Xie G, Zheng X. Theabrownin and Poria cocos Polysaccharide Improve Lipid Metabolism via Modulation of Bile Acid and Fatty Acid Metabolism. Front Pharmacol 2022;13:875549. [DOI: 10.3389/fphar.2022.875549] [Reference Citation Analysis]
468 Emamat H, Ghalandari H, Tangestani H, Abdollahi A, Hekmatdoost A. Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism. EXCLI J 2020;19:620-6. [PMID: 32483408 DOI: 10.17179/excli2020-1226] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
469 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
470 Cazzo E, Jimenez LS, Gestic MA, Utrini MP, Chaim FHM, Chaim FDM, Pareja JC, Chaim EA. Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features. OBES SURG 2018;28:187-94. [DOI: 10.1007/s11695-017-2829-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
471 Hadjihambi A. Cerebrovascular alterations in NAFLD: Is it increasing our risk of Alzheimer's disease? Anal Biochem 2021;:114387. [PMID: 34537182 DOI: 10.1016/j.ab.2021.114387] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
472 Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, Hatami B, Hekmatdoost A. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial. BMC Gastroenterol. 2019;19:133. [PMID: 31345163 DOI: 10.1186/s12876-019-1055-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
473 Koo BK, Allison MA, Criqui MH, Denenberg JO, Wright CM. The association between liver fat and systemic calcified atherosclerosis. J Vasc Surg 2020;71:204-211.e4. [PMID: 31153702 DOI: 10.1016/j.jvs.2019.03.044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
474 Gambato M, Villanueva A, Abraldes JG, Altamirano J, Forns X. Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. J Hepatol 2015;63:753-62. [PMID: 26095181 DOI: 10.1016/j.jhep.2015.06.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
475 Jin K, Liu Y, Shi Y, Zhang H, Sun Y, Zhangyuan G, Wang F, Yu W, Wang J, Tao X, Chen X, Zhang W, Sun B. PTPROt aggravates inflammation by enhancing NF-κB activation in liver macrophages during nonalcoholic steatohepatitis. Theranostics 2020;10:5290-304. [DOI: 10.7150/thno.42658] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
476 Oseini AM, Cole BK, Issa D, Feaver RE, Sanyal AJ. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. Hepatol Int 2018;12:6-16. [PMID: 29299759 DOI: 10.1007/s12072-017-9838-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
477 Lugari S, Mantovani A, Nascimbeni F, Lonardo A. Hypothyroidism and nonalcoholic fatty liver disease - a chance association? Horm Mol Biol Clin Investig 2018;41:/j/hmbci. [PMID: 30367792 DOI: 10.1515/hmbci-2018-0047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
478 Yu Z, Wang S, Hou H, Ma L, Zhu Y. Lipidomic Profiling Reveals the Effect of Egg Components on Nonalcoholic Steatosis in HepG2 Cells and Its Involved Mechanisms. Eur J Lipid Sci Technol 2020;122:1900451. [DOI: 10.1002/ejlt.201900451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
479 Han J, Guo X, Koyama T, Kawai D, Zhang J, Yamaguchi R, Zhou X, Motoo Y, Satoh T, Yamada S. Zonarol Protected Liver from Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease in a Mouse Model. Nutrients 2021;13:3455. [PMID: 34684455 DOI: 10.3390/nu13103455] [Reference Citation Analysis]
480 Hou C, Feng W, Wei S, Wang Y, Xu X, Wei J, Ma Z, Du Y, Guo J, He Y, Kong F, Tang R, Zheng K. Bioinformatics Analysis of Key Differentially Expressed Genes in Nonalcoholic Fatty Liver Disease Mice Models. Gene Expr 2018;19:25-35. [PMID: 30135001 DOI: 10.3727/105221618X15341831737687] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
481 Maev IV, Samsonov AA, Lazebnik LB, Golovanova EV, Pavlov CS, Vovk EI, Ratziu V, Starostin KM. A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Adv Ther 2020;37:4627-40. [PMID: 32939691 DOI: 10.1007/s12325-020-01493-w] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
482 Swift O, Sharma S, Ramanarayanan S, Umar H, Laws KR, Vilar E, Farrington K. Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis. Clinical Kidney Journal 2021. [DOI: 10.1093/ckj/sfab230] [Reference Citation Analysis]
483 Mantovani A, Dauriz M, Sandri D, Bonapace S, Zoppini G, Tilg H, Byrne CD, Targher G. Association between non‐alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta‐analysis. Liver Int 2019;39:758-69. [DOI: 10.1111/liv.14044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
484 Hartleb M, Barański K, Zejda J, Chudek J, Więcek A. Non-alcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey. Liver Int 2017;37:1706-14. [PMID: 28489307 DOI: 10.1111/liv.13471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
485 Drummen M, Dorenbos E, Vreugdenhil ACE, Raben A, Fogelholm M, Westerterp-plantenga MS, Adam TC. Long-term effects of increased protein intake after weight loss on intrahepatic lipid content and implications for insulin sensitivity: a PREVIEW study. American Journal of Physiology-Endocrinology and Metabolism 2018;315:E885-91. [DOI: 10.1152/ajpendo.00162.2018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
486 Berasain C, Avila MA. Regulation of hepatocyte identity and quiescence. Cell Mol Life Sci 2015;72:3831-51. [DOI: 10.1007/s00018-015-1970-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
487 Van de Velde F, Bekaert M, Geerts A, Hoorens A, Batens AH, Shadid S, Ouwens M, Van Nieuwenhove Y, Lapauw B. Insulin resistance associates with hepatic lobular inflammation in subjects with obesity. Endocr Connect 2019;8:1294-301. [PMID: 31470414 DOI: 10.1530/EC-19-0366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
488 Cho Y, Chang Y, Ryu S, Jung HS, Kim CW, Oh H, Kim MK, Sohn W, Shin H, Wild SH, Byrne CD. Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. Hepatol Commun 2022. [PMID: 35503803 DOI: 10.1002/hep4.1975] [Reference Citation Analysis]
489 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
490 Paquissi FC. Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. Front Immunol 2016;7:490. [PMID: 27891128 DOI: 10.3389/fimmu.2016.00490] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
491 Aghemo A, Alekseeva OP, Angelico F, Bakulin IG, Bakulina NV, Bordin D, Bueverov AO, Drapkina OM, Gillessen A, Kagarmanova EM, Korochanskaya NV, Kucheryavii UA, Lazebnik LB, Livzan MA, Maev IV, Martynov AI, Osipenko MF, Sas EI, Starodubova A, Uspensky YP, Vinnitskaya EV, Yakovenko EP, Yakovlev AA. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Annals of Medicine 2022;54:1548-60. [DOI: 10.1080/07853890.2022.2069854] [Reference Citation Analysis]
492 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
493 Mauricio D, Alonso N, Gratacòs M. Chronic Diabetes Complications: The Need to Move beyond Classical Concepts. Trends Endocrinol Metab 2020;31:287-95. [PMID: 32033865 DOI: 10.1016/j.tem.2020.01.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
494 Yadav AK, Sata TN, Verma D, Mishra AK, Sah AK, Hossain MM, Pant K, Venugopal SK. Free fatty acid-induced miR-181a-5p stimulates apoptosis by targeting XIAP and Bcl2 in hepatic cells. Life Sci 2022;:120625. [PMID: 35551953 DOI: 10.1016/j.lfs.2022.120625] [Reference Citation Analysis]
495 Sarkisova EA, Chumak AA, Ovsyannikova LM, Alekhina LM, Nosach OV, Gasanova EO, Shyiko TO. THE EFFECT OF APPLICATION OF ANTIOXIDANT THERAPY IN THE TREATMENT OF NON-ALKOHOLIC STEATOHEPATATIS IN CHORNOBYL NPP ACCIDENT SUFFERERS IN THE REMOTE PERIOD AFTER IRRADIATION. Probl Radiac Med Radiobiol 2018;23:452-61. [PMID: 30582862 DOI: 10.33145/2304-8336-2018-23-452-461] [Reference Citation Analysis]
496 Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Akita T, Tanaka J. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2017;1:899-910. [PMID: 29404500 DOI: 10.1002/hep4.1105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
497 Xu QY, Li H, Cao HX, Pan Q, Fan JG. APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2020;2020:8869674. [PMID: 33294458 DOI: 10.1155/2020/8869674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
498 Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, Esmat G, George J, Marchesini G, Novak K, Ocama P, Ratziu V, Razavi H, Romero-Gómez M, Silva M, Spearman CW, Tacke F, Tsochatzis EA, Yilmaz Y, Younossi ZM, Wong VW, Zelber-Sagi S, Cortez-Pinto H, Anstee QM; NAFLD policy review collaborators. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol 2021:S0168-8278(21)02168-1. [PMID: 34895743 DOI: 10.1016/j.jhep.2021.10.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
499 Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, Schattenberg JM. Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Dig Dis Sci 2020;65:2112-9. [DOI: 10.1007/s10620-019-05986-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
500 Huang Z, Ng K, Chen H, Deng W, Li Y. Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement. Front Endocrinol 2022;12:739875. [DOI: 10.3389/fendo.2021.739875] [Reference Citation Analysis]
501 Roohani S, Tacke F. Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. Int J Mol Sci 2021;22:7249. [PMID: 34298870 DOI: 10.3390/ijms22147249] [Reference Citation Analysis]
502 Bhowmick S, Singh V, Jash S, Lal M, Sinha Roy S. Mitochondrial metabolism and calcium homeostasis in the development of NAFLD leading to hepatocellular carcinoma. Mitochondrion 2021;58:24-37. [PMID: 33581332 DOI: 10.1016/j.mito.2021.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
503 Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease. Lipids Health Dis 2021;20:134. [PMID: 34629059 DOI: 10.1186/s12944-021-01561-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
504 Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425-443. [PMID: 27091791 DOI: 10.1016/j.jhep.2016.04.005] [Cited by in Crossref: 190] [Cited by in F6Publishing: 185] [Article Influence: 31.7] [Reference Citation Analysis]
505 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
506 Al-Mrabeh A. β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies. Biomedicines 2021;9:226. [PMID: 33672162 DOI: 10.3390/biomedicines9020226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
507 Gao L, Wang PX, Zhang Y, Yu CJ, Ji Y, Wang X, Zhang P, Jiang X, Jin H, Huang Z, Zhang ZR, Li H. Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis. J Hepatol. 2016;65:125-136. [PMID: 27032381 DOI: 10.1016/j.jhep.2016.03.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
508 Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol Life Sci. 2018;75:2951-2961. [PMID: 29789866 DOI: 10.1007/s00018-018-2838-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
509 Moise CG, Donoiu I, Târtea GC, Mirea O, Rogoveanu I. Assessment of Left Ventricular Diastolic Function in Young Adults with Nonalcoholic Fatty Liver Disease. Curr Health Sci J 2021;47:23-7. [PMID: 34211743 DOI: 10.12865/CHSJ.47.01.04] [Reference Citation Analysis]
510 Gao F, He Q, Li G, Huang OY, Tang LJ, Wang XD, Targher G, Byrne CD, Luo JW, Zheng MH. A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. Liver Int 2021. [PMID: 34564946 DOI: 10.1111/liv.15064] [Reference Citation Analysis]
511 Lee SB, Kim MK, Kang S, Park K, Kim JH, Baik SJ, Nam JS, Ahn CW, Park JS. Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults. Endocrinol Metab (Seoul) 2019;34:179-86. [PMID: 31257745 DOI: 10.3803/EnM.2019.34.2.179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
512 Zhao Z, Chen L, Zhao Y, Wang C, Duan C, Yang G, Niu C, Li S. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.Appl Microbiol Biotechnol. 2020;104:5273-5282. [PMID: 32335723 DOI: 10.1007/s00253-020-10633-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
513 Sargeant JA, Bawden S, Aithal GP, Simpson EJ, Macdonald IA, Turner MC, Cegielski J, Smith K, Dorling JL, Gowland PA, Nimmo MA, King JA. Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease. Eur J Appl Physiol 2018;118:817-28. [PMID: 29411128 DOI: 10.1007/s00421-018-3818-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
514 Zhang QY, Zhao LP, Tian XX, Yan CH, Li Y, Liu YX, Wang PX, Zhang XJ, Han YL. The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance. Hepatology 2017;66:834-54. [PMID: 28508477 DOI: 10.1002/hep.29257] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
515 Roerecke M, Nanau R, Rehm J, Neuman M. Ethnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic Steatosis. EBioMedicine. 2016;8:317-330. [PMID: 27428441 DOI: 10.1016/j.ebiom.2016.04.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
516 Hong SH, Hwang SY, Kim JA, Lee YB, Roh E, Kim NH, Seo JA, Kim SG, Kim NH, Choi KM, Baik SH, Yoo HJ. Comparison of anthropometric indices for the screening of nonalcoholic fatty liver disease in pre- and postmenopausal women. Menopause 2020;27:88-94. [PMID: 31613826 DOI: 10.1097/GME.0000000000001419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
517 Trindade AJ, Thaniyavarn T, Hashemi N, Coppolino A 3rd, Kennedy JC, Mallidi HR, El-Chemaly S, Goldberg HJ. 1-year outcomes for lung transplantation recipients with non-alcoholic fatty liver disease. ERJ Open Res 2021;7:00103-2021. [PMID: 34435032 DOI: 10.1183/23120541.00103-2021] [Reference Citation Analysis]
518 He C, Cheng D, Wang H, Wu K, Zhu Y, Lu N. Helicobacter pylori infection aggravates diet-induced nonalcoholic fatty liver in mice. Clinics and Research in Hepatology and Gastroenterology 2018;42:360-7. [DOI: 10.1016/j.clinre.2017.12.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
519 Zhang L, Wang Y, Wu F, Wang X, Feng Y, Wang Y. MDG, an Ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila. Int J Biol Macromol 2022;196:23-34. [PMID: 34920070 DOI: 10.1016/j.ijbiomac.2021.12.036] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
520 Papic N, Samadan L, Vrsaljko N, Radmanic L, Jelicic K, Simicic P, Svoboda P, Lepej SZ, Vince A. Distinct Cytokine Profiles in Severe COVID-19 and Non-Alcoholic Fatty Liver Disease. Life 2022;12:795. [DOI: 10.3390/life12060795] [Reference Citation Analysis]
521 Goodarzi R, Sabzian K, Shishehbor F, Mansoori A. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials: Turmeric/curcumin supplementation and liver enzymes. Phytotherapy Research 2019;33:561-70. [DOI: 10.1002/ptr.6270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
522 Hellerbrand C, Massoumi R. Cylindromatosis-A Protective Molecule against Liver Diseases: CYLD IN LIVER DISEASE. Med Res Rev 2016;36:342-59. [DOI: 10.1002/med.21381] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
523 Chen YS, Chen D, Shen C, Chen M, Jin CH, Xu CF, Yu CH, Li YM. A novel model for predicting fatty liver disease by means of an artificial neural network. Gastroenterol Rep (Oxf) 2021;9:31-7. [PMID: 33747524 DOI: 10.1093/gastro/goaa035] [Reference Citation Analysis]
524 Park HS, Song JW, Park JH, Lim BK, Moon OS, Son HY, Lee JH, Gao B, Won YS, Kwon HJ. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. Autophagy 2020;:1-16. [PMID: 33190588 DOI: 10.1080/15548627.2020.1834711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
525 Tao S, Yang Y, Li J, Wang H, Ma Y. Bixin Attenuates High-Fat Diet-Caused Liver Steatosis and Inflammatory Injury through Nrf2/PPARα Signals. Oxid Med Cell Longev 2021;2021:6610124. [PMID: 33603948 DOI: 10.1155/2021/6610124] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
526 Choi JW, Lee CH, Park JS. Comparison of laboratory indices of non-alcoholic fatty liver disease for the detection of incipient kidney dysfunction. PeerJ 2019;7:e6524. [PMID: 30867987 DOI: 10.7717/peerj.6524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
527 Cherkashchenko NA, Livzan MA, Krolevets TS. [Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease]. Ter Arkh 2020;92:29-36. [PMID: 33346459 DOI: 10.26442/00403660.2020.08.000764] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
528 Kapoor N, Audsley J, Rupali P, Sasadeusz J, Paul TV, Thomas N, Lewin SR. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. AIDS 2019;33:1105-15. [PMID: 31045941 DOI: 10.1097/QAD.0000000000002161] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
529 Sun L, Ling Y, Jiang J, Wang D, Wang J, Li J, Wang X, Wang H. Differential mechanisms regarding triclosan vs. bisphenol A and fluorene-9-bisphenol induced zebrafish lipid-metabolism disorders by RNA-Seq. Chemosphere 2020;251:126318. [DOI: 10.1016/j.chemosphere.2020.126318] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
530 Ahadi S, Gharekhani A, Shiva A. Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. Arab Journal of Gastroenterology 2019;20:189-97. [DOI: 10.1016/j.ajg.2019.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
531 Zhang R, Wang M, Wang M, Zhang L, Ding Y, Tang Z, Fu Z, Fan H, Zhang W, Wang J. Vitamin D Level and Vitamin D Receptor Genetic Variation Were Involved in the Risk of Non-Alcoholic Fatty Liver Disease: A Case-Control Study. Front Endocrinol (Lausanne) 2021;12:648844. [PMID: 34421816 DOI: 10.3389/fendo.2021.648844] [Reference Citation Analysis]
532 Stenkula KG, Stenblom EL, Montelius C, Egecioglu E, Erlanson-Albertsson C. Thylakoids reduce body fat and fat cell size by binding to dietary fat making it less available for absorption in high-fat fed mice. Nutr Metab (Lond) 2017;14:4. [PMID: 28096887 DOI: 10.1186/s12986-016-0160-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
533 Chen Y, Ma K. NLRC4 inflammasome activation regulated by TNF-α promotes inflammatory responses in nonalcoholic fatty liver disease. Biochemical and Biophysical Research Communications 2019;511:524-30. [DOI: 10.1016/j.bbrc.2019.02.099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
534 Holzner ML, Florman S, Schwartz ME, Tabrizian P. Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma. HPB (Oxford) 2021:S1365-182X(21)01587-2. [PMID: 34544629 DOI: 10.1016/j.hpb.2021.08.943] [Reference Citation Analysis]
535 Lira MMP, de Medeiros Filho JEM, Baccin Martins VJ, da Silva G, de Oliveira Junior FA, de Almeida Filho ÉJB, Silva AS, Henrique da Costa-Silva J, de Brito Alves JL. Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. PLoS One 2020;15:e0237360. [PMID: 32845887 DOI: 10.1371/journal.pone.0237360] [Reference Citation Analysis]
536 Mantovani A, Sani E, Fassio A, Colecchia A, Viapiana O, Gatti D, Idolazzi L, Rossini M, Salvagno G, Lippi G, Zoppini G, Byrne C, Bonora E, Targher G. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Diabetes & Metabolism 2019;45:347-55. [DOI: 10.1016/j.diabet.2018.10.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
537 Kasper P, Breuer S, Hoffmann T, Vohlen C, Janoschek R, Schmitz L, Appel S, Fink G, Hünseler C, Quaas A, Demir M, Lang S, Steffen HM, Martin A, Schramm C, Bürger M, Mahabir E, Goeser T, Dötsch J, Hucklenbruch-Rother E, Bae-Gartz I. Maternal Exercise Mediates Hepatic Metabolic Programming via Activation of AMPK-PGC1α Axis in the Offspring of Obese Mothers. Cells 2021;10:1247. [PMID: 34069390 DOI: 10.3390/cells10051247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
538 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2021:S1590-8658(21)00214-0. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Reference Citation Analysis]
539 Guo R, Nair S, Zhang Y, Ren J. Adiponectin deficiency rescues high-fat diet-induced hepatic injury, apoptosis and autophagy loss despite persistent steatosis. Int J Obes (Lond) 2017;41:1403-12. [PMID: 28559541 DOI: 10.1038/ijo.2017.128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
540 Sun X, Chen R, Yan G, Chen Z, Yuan H, Huang W, Lu Y. Gender-specific associations between apolipoprotein A1 and arterial stiffness in patients with nonalcoholic fatty liver disease. PeerJ 2020;8:e9757. [PMID: 32874784 DOI: 10.7717/peerj.9757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
541 Lonardo A, Targher G. NAFLD: Is There Anything New under the Sun? Int J Mol Sci 2017;18:E1955. [PMID: 28895919 DOI: 10.3390/ijms18091955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
542 Ni L, Yu D, Wu T, Jin F. Gender-specific association between non-alcoholic fatty liver disease and type 2 diabetes mellitus among a middle-aged and elderly Chinese population: An observational study. Medicine (Baltimore) 2021;100:e24743. [PMID: 33578624 DOI: 10.1097/MD.0000000000024743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
543 Kao WY, Lin YF, Chang IW, Chen CL, Tang JH, Chang CC, Chang YJ, Wang W. Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis. J Chin Med Assoc 2021;84:261-6. [PMID: 33306598 DOI: 10.1097/JCMA.0000000000000469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
544 Song DS, Chang UI, Kang SG, Song SW, Yang JM. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2019;13:658-68. [PMID: 30970434 DOI: 10.5009/gnl18439] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
545 Barbosa PO, Souza MO, Silva MPS, Santos GT, Silva ME, Bermano G, Freitas RN. Açaí (Euterpe oleracea Martius) supplementation improves oxidative stress biomarkers in liver tissue of dams fed a high-fat diet and increases antioxidant enzymes' gene expression in offspring. Biomed Pharmacother 2021;139:111627. [PMID: 33965728 DOI: 10.1016/j.biopha.2021.111627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
546 Mahady SE, Adams LA. Burden of non-alcoholic fatty liver disease in Australia: Burden of fatty liver in Australia. Journal of Gastroenterology and Hepatology 2018;33:1-11. [DOI: 10.1111/jgh.14270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
547 Zhang P, Feng W, Chu X, Sun X, Zhu D, Bi Y. A newly noninvasive model for prediction of non-alcoholic fatty liver disease: utility of serum prolactin levels. BMC Gastroenterol 2019;19:202. [PMID: 31775658 DOI: 10.1186/s12876-019-1120-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
548 Hamed AM, El-Kharashi OA, Boctor SS, Abd-Elaziz LF. Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats. Biomed Pharmacother 2017;85:68-78. [PMID: 27930988 DOI: 10.1016/j.biopha.2016.11.114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
549 Han S, Zhu F, Huang X, Yan P, Xu K, Shen F, Sun J, Yang Z, Jin G, Teng Y. Maternal obesity accelerated non-alcoholic fatty liver disease in offspring mice by reducing autophagy. Exp Ther Med 2021;22:716. [PMID: 34007325 DOI: 10.3892/etm.2021.10148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
550 Liu M, Wang J, Zeng J, Cao X, He Y. Association of NAFLD With Diabetes and the Impact of BMI Changes: A 5-Year Cohort Study Based on 18,507 Elderly. The Journal of Clinical Endocrinology & Metabolism 2017;102:1309-16. [DOI: 10.1210/jc.2016-3440] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
551 Bisaccia G, Ricci F, Mantini C, Tana C, Romani GL, Schiavone C, Gallina S. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. SAGE Open Med 2020;8:2050312120933804. [PMID: 32612827 DOI: 10.1177/2050312120933804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
552 Kim YK, Kwon OS, Her KH. The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: An observational Study. Medicine (Baltimore) 2019;98:e16018. [PMID: 31277096 DOI: 10.1097/MD.0000000000016018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
553 Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.Eur J Gastroenterol Hepatol. 2019;31:613-617. [PMID: 30920975 DOI: 10.1097/MEG.0000000000001369] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
554 Zou Y, Hu C, Kuang M, Chai Y. Remnant cholesterol/high-density lipoprotein cholesterol ratio is a new powerful tool for identifying non-alcoholic fatty liver disease. BMC Gastroenterol 2022;22:134. [PMID: 35331166 DOI: 10.1186/s12876-022-02216-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
555 Zhang Y, Tang K, Deng Y, Chen R, Liang S, Xie H, He Y, Chen Y, Yang Q. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. Biomed Pharmacother. 2018;102:1025-1036. [PMID: 29710519 DOI: 10.1016/j.biopha.2018.03.158] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
556 Xiong G, Huang C, Zou Y, Tao Z, Zou J, Huang J, M.a B. Associations of Urinary Phytoestrogen Concentrations with Nonalcoholic Fatty Liver Disease among Adults. Journal of Healthcare Engineering 2022;2022:1-13. [DOI: 10.1155/2022/4912961] [Reference Citation Analysis]
557 Zhao Y, Wang F, Gao L, Xu L, Tong R, Lin N, Su Y, Yan Y, Gao Y, He J, Kong L, Yuan A, Zhuge Y, Pu J. Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Metabolic Dysfunctions in Nonalcoholic Fatty Liver Disease in Mice. Hepatology 2018;68:897-917. [PMID: 29573006 DOI: 10.1002/hep.29889] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
558 Gawlik-Kotelnicka O, Strzelecki D. Adiposity in Depression or Depression in Adiposity? The Role of Immune-Inflammatory-Microbial Overlap. Life (Basel) 2021;11:117. [PMID: 33557031 DOI: 10.3390/life11020117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
559 Baars T, Sowa JP, Neumann U, Hendricks S, Jinawy M, Kälsch J, Gerken G, Rassaf T, Heider D, Canbay A. Liver parameters as part of a non-invasive model for prediction of all-cause mortality after myocardial infarction. Arch Med Sci 2020;16:71-80. [PMID: 32051708 DOI: 10.5114/aoms.2018.75678] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
560 Tsukahara Y, Ferran B, Minetti ET, Chong BSH, Gower AC, Bachschmid MM, Matsui R. Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis. Antioxidants (Basel) 2022;11:867. [PMID: 35624731 DOI: 10.3390/antiox11050867] [Reference Citation Analysis]
561 Tsujita Y, Sofue K, Ueshima E, Ueno Y, Hori M, Murakami T. Clinical Application of Quantitative MR Imaging in Nonalcoholic Fatty Liver Disease. Magn Reson Med Sci 2022. [PMID: 35584952 DOI: 10.2463/mrms.rev.2021-0152] [Reference Citation Analysis]
562 Gu D, Yi H, Jiang K, Fakhar SH, Shi J, He Y, Liu B, Guo Y, Fan X, Li S. Transcriptome analysis reveals the efficacy of ginsenoside-Rg1 in the treatment of nonalcoholic fatty liver disease. Life Sci 2021;267:118986. [PMID: 33385408 DOI: 10.1016/j.lfs.2020.118986] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
563 Dong M, Liu S, Wang M, Wang Y, Xin Y, Xuan S. Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han population. J Int Med Res 2021;49:3000605211019263. [PMID: 34275374 DOI: 10.1177/03000605211019263] [Reference Citation Analysis]
564 VanWagner LB. New insights into NAFLD and subclinical coronary atherosclerosis. J Hepatol 2018;68:890-2. [PMID: 29410378 DOI: 10.1016/j.jhep.2018.01.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
565 Bonsembiante L, Targher G, Maffeis C. Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition? Eur J Clin Nutr 2021. [PMID: 34006994 DOI: 10.1038/s41430-021-00928-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
566 Tang P, Low HB, Png CW, Torta F, Kumar JK, Lim HY, Zhou Y, Yang H, Angeli V, Shabbir A, Tai ES, Flavell RA, Dong C, Wenk MR, Yang DY, Zhang Y. Protective Function of Mitogen-Activated Protein Kinase Phosphatase 5 in Aging- and Diet-Induced Hepatic Steatosis and Steatohepatitis. Hepatol Commun 2019;3:748-62. [PMID: 31168510 DOI: 10.1002/hep4.1324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
567 Kalra S, Bhattacharya S, Rawal P. Hepatocrinology. Med Sci (Basel) 2021;9:39. [PMID: 34205986 DOI: 10.3390/medsci9020039] [Reference Citation Analysis]
568 Sliz E, Sebert S, Würtz P, Kangas AJ, Soininen P, Lehtimäki T, Kähönen M, Viikari J, Männikkö M, Ala-Korpela M, Raitakari OT, Kettunen J. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Hum Mol Genet 2018;27:2214-23. [PMID: 29648650 DOI: 10.1093/hmg/ddy124] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 17.3] [Reference Citation Analysis]
569 Wijarnpreecha K, Panjawatanan P, Thongprayoon C, Jaruvongvanich V, Ungprasert P. Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol 2018;24:12-7. [PMID: 29451179 DOI: 10.4103/sjg.SJG_237_17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
570 Hu W, Zhao J, Chen H, Xiong L, Wang W. Polysaccharides from Cyclocarya paliurus: Chemical composition and lipid-lowering effect on rats challenged with high-fat diet. Journal of Functional Foods 2017;36:262-73. [DOI: 10.1016/j.jff.2017.07.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
571 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Moyses HE, Clough GF, Wright M, Patel J, Bindels L, Delzenne NM, Calder PC, Byrne CD. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. Contemp Clin Trials 2018;71:113-23. [PMID: 29787859 DOI: 10.1016/j.cct.2018.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
572 Gupta H, Min B, Ganesan R, Gebru YA, Sharma SP, Park E, Won S, Jeong J, Lee S, Cha M, Kwon G, Jeong M, Hyun J, Eom J, Park H, Yoon S, Choi M, Kim D, Suk K. Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines 2022;10:550. [DOI: 10.3390/biomedicines10030550] [Reference Citation Analysis]
573 Cheung A, Ahmed A. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. Clin Exp Gastroenterol 2021;14:457-65. [PMID: 34819740 DOI: 10.2147/CEG.S226130] [Reference Citation Analysis]
574 Kaur J, Kumar V, Kumar V, Shafi S, Khare P, Mahajan N, Bhadada SK, Kondepudi KK, Bhunia RK, Kuhad A, Bishnoi M. Combination of TRP channel dietary agonists induces energy expending and glucose utilizing phenotype in HFD-fed mice. Int J Obes (Lond) 2021. [PMID: 34564707 DOI: 10.1038/s41366-021-00967-3] [Reference Citation Analysis]
575 Skat-Rørdam J, Ipsen DH, Hardam PD, Latta M, Lykkesfeldt J, Tveden-Nyborg P. Differential Effects of Dietary Components on Glucose Intolerance and Non-Alcoholic Steatohepatitis. Nutrients 2021;13:2523. [PMID: 34444683 DOI: 10.3390/nu13082523] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
576 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
577 Molyvdas A, Georgopoulou U, Lazaridis N, Hytiroglou P, Dimitriadis A, Foka P, Vassiliadis T, Loli G, Phillipidis A, Zebekakis P, Germenis AE, Speletas M, Germanidis G. The role of the NLRP3 inflammasome and the activation of IL-1β in the pathogenesis of chronic viral hepatic inflammation. Cytokine 2018;110:389-96. [PMID: 29803661 DOI: 10.1016/j.cyto.2018.04.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
578 Käräjämäki AJ, Hukkanen J, Ukkola O. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. Annals of Medicine 2018;50:371-80. [DOI: 10.1080/07853890.2018.1492147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
579 Han Q, Li H, Jia M, Wang L, Zhao Y, Zhang M, Zhang Q, Meng Z, Shao J, Yang Y, Zhu L. Age-related changes in metabolites in young donor livers and old recipient sera after liver transplantation from young to old rats. Aging Cell 2021;20:e13425. [PMID: 34157207 DOI: 10.1111/acel.13425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
580 Quesada-Vázquez S, Colom-Pellicer M, Navarro-Masip È, Aragonès G, Del Bas JM, Caimari A, Escoté X. Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice. Nutrients 2021;13:3532. [PMID: 34684533 DOI: 10.3390/nu13103532] [Reference Citation Analysis]
581 Dassanayake AS. Nonalcoholic Fatty Liver Disease: Identifying the Disease Burden in Sri Lanka. Euroasian J Hepatogastroenterol 2018;8:69-72. [PMID: 29963467 DOI: 10.5005/jp-journals-10018-1263] [Reference Citation Analysis]
582 Yan H, Li T, Wang Y, Li H, Xu J, Lu X. Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 2019;46:1101-10. [PMID: 31397492 DOI: 10.1111/1440-1681.13159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
583 Braude MR, Con D, Lubel J, Bidwai A, Nguyen HT, Sharmamiglani S, Clarke D, Dev A, Sievert W. Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools. Hepatol Int 2021;15:812-20. [PMID: 34081288 DOI: 10.1007/s12072-021-10195-6] [Reference Citation Analysis]
584 Eslam M, Ahmed A, Després JP, Jha V, Halford JCG, Wei Chieh JT, Harris DCH, Nangaku M, Colagiuri S, Targher G, Joshi S, Byrne CD, Khunti K, Nguyen MH, Gish RG, George J. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol 2021;6:743-53. [PMID: 34265276 DOI: 10.1016/S2468-1253(21)00132-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
585 Babu AF, Csader S, Männistö V, Tauriainen MM, Pentikäinen H, Savonen K, Klåvus A, Koistinen V, Hanhineva K, Schwab U. Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool. Sci Rep 2022;12:6485. [PMID: 35444259 DOI: 10.1038/s41598-022-10481-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
586 Zelicha H, Schwarzfuchs D, Shelef I, Gepner Y, Tsaban G, Tene L, Yaskolka Meir A, Bilitzky A, Komy O, Cohen N, Bril N, Rein M, Serfaty D, Kenigsbuch S, Chassidim Y, Sarusi B, Thiery J, Ceglarek U, Stumvoll M, Blüher M, Haviv YS, Stampfer MJ, Rudich A, Shai I. Changes of renal sinus fat and renal parenchymal fat during an 18-month randomized weight loss trial. Clinical Nutrition 2018;37:1145-53. [DOI: 10.1016/j.clnu.2017.04.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
587 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh) 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 17.7] [Reference Citation Analysis]
588 Jiang X, Li Y, Wang W, Han X, Han J, Chen M, Zhang J, Wang C, Li S, Luo J, Wang X, Xu Y, Xu Y, Cheng J, Si S. Nuclear Factor Erythroid 2 Related Factor 2 Activator JC-5411 Inhibits Atherosclerosis Through Suppression of Inflammation and Regulation of Lipid Metabolism. Front Pharmacol 2020;11:532568. [PMID: 33442380 DOI: 10.3389/fphar.2020.532568] [Reference Citation Analysis]
589 Sun Y, Chen S, Zhao X, Wang Y, Lan Y, Jiang X, Gao X, Wu S, Wang L. Adherence to the dietary approaches to stop hypertension diet and non-alcoholic fatty liver disease. Liver Int 2022. [PMID: 34990079 DOI: 10.1111/liv.15156] [Reference Citation Analysis]
590 Majnooni MB, Ataee M, Bahrami G, Heydarpour F, Aneva IY, Farzaei MH, Ahmadi-Juoibari T. The effects of co-administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: A randomized clinical trial. Phytother Res 2021. [PMID: 34533249 DOI: 10.1002/ptr.7279] [Reference Citation Analysis]
591 Asghar MS, Hassan M, Rasheed U, Haider Kazmi SJ, Khan NA, Khalid F, Anum A, Anwar S. Impact of Fasting Lipid Profile on Chronic Kidney Disease Patients Having Fatty Liver Disease. Cureus 2020;12:e11146. [PMID: 33251056 DOI: 10.7759/cureus.11146] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
592 Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310. [PMID: 28218263 DOI: 10.1038/nrneph.2017.16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 23.0] [Reference Citation Analysis]
593 Wang S, Cai B, Han X, Gao Y, Zhang X, Wang R, Zhang Y, Chen Q. Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20148. [PMID: 32384501 DOI: 10.1097/MD.0000000000020148] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
594 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut 2022;71:156-62. [PMID: 33303564 DOI: 10.1136/gutjnl-2020-323082] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 43.0] [Reference Citation Analysis]
595 Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Adv Pharm Bull. 2020;10:542-555. [PMID: 33072533 DOI: 10.34172/apb.2020.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
596 Si Z, Guan X, Teng X, Peng X, Wan Z, Li Q, Chen G, Tan J, Li J. Identification of CYP46A1 as a new regulator of lipid metabolism through CRISPR-based whole-genome screening. FASEB J 2020;34:13776-91. [PMID: 32816363 DOI: 10.1096/fj.202001067R] [Reference Citation Analysis]
597 Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol 2022:S0168-8278(22)00375-0. [PMID: 35750137 DOI: 10.1016/j.jhep.2022.06.012] [Reference Citation Analysis]
598 Basaranoglu M, Najjar SM, Demirbag AE, Senturk H. Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list. World J Hepatol 2016; 8(7): 376-384 [PMID: 26981175 DOI: 10.4254/wjh.v8.i7.376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
599 Afolabi PR, Scorletti E, Smith DE, Almehmadi AA, Calder PC, Byrne CD. The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the 13C-ketoisocaproate breath test. J Breath Res 2018;12:046002. [PMID: 29943733 DOI: 10.1088/1752-7163/aacf12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
600 Mikolasevic I, Milic S, Turk Wensveen T, Grgic I, Jakopcic I, Stimac D, Wensveen F, Orlic L. Nonalcoholic fatty liver disease - A multisystem disease? World J Gastroenterol 2016; 22(43): 9488-9505 [PMID: 27920470 DOI: 10.3748/wjg.v22.i43.9488] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 85] [Article Influence: 15.2] [Reference Citation Analysis]
601 Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. Journal of Hepatology 2016;65:589-600. [DOI: 10.1016/j.jhep.2016.05.013] [Cited by in Crossref: 515] [Cited by in F6Publishing: 465] [Article Influence: 85.8] [Reference Citation Analysis]
602 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
603 Zou J, Xiong H, Zhang H, Hu C, Lu S, Zou Y. Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02099-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
604 Peters HPF, Schrauwen P, Verhoef P, Byrne CD, Mela DJ, Pfeiffer AFH, Risérus U, Rosendaal FR, Schrauwen-Hinderling V. Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. J Nutr Sci 2017;6:e15. [PMID: 28630692 DOI: 10.1017/jns.2017.13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
605 Starekova J, Reeder SB. Liver fat quantification: where do we stand? Abdom Radiol (NY) 2020;45:3386-99. [PMID: 33025153 DOI: 10.1007/s00261-020-02783-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
606 Flessa CM, Kyrou I, Nasiri-Ansari N, Kaltsas G, Papavassiliou AG, Kassi E, Randeva HS. Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives. Curr Obes Rep 2021;10:134-61. [PMID: 33751456 DOI: 10.1007/s13679-021-00431-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
607 Ivashkin VT, Maevskaya MV, Shirokova EN, Maev IV, Samsonov AA, Sas EI, Palgova LK, Starostin K. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies. Drugs Real World Outcomes 2021;8:369-82. [PMID: 33993460 DOI: 10.1007/s40801-021-00250-x] [Reference Citation Analysis]
608 Mabasa L, Samodien E, Sangweni NF, Pheiffer C, Louw J, Johnson R. In Utero One-Carbon Metabolism Interplay and Metabolic Syndrome in Cardiovascular Disease Risk Reduction. Mol Nutr Food Res 2020;64:e1900377. [PMID: 31408914 DOI: 10.1002/mnfr.201900377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
609 Meroni M, Longo M, Erconi V, Valenti L, Gatti S, Fracanzani AL, Dongiovanni P. mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients 2019;11:E2597. [PMID: 31671785 DOI: 10.3390/nu11112597] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
610 Dembek A, Laggai S, Kessler SM, Czepukojc B, Simon Y, Kiemer AK, Hoppstädter J. Hepatic interleukin-6 production is maintained during endotoxin tolerance and facilitates lipid accumulation. Immunobiology 2017;222:786-96. [DOI: 10.1016/j.imbio.2017.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
611 Skat-rørdam J, Pedersen K, Skovsted GF, Gregersen I, Vangsgaard S, Ipsen DH, Latta M, Lykkesfeldt J, Tveden-nyborg P. Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig. Antioxidants 2022;11:69. [DOI: 10.3390/antiox11010069] [Reference Citation Analysis]
612 Niederseer D, Wernly S, Bachmayer S, Wernly B, Bakula A, Huber-Schönauer U, Semmler G, Schmied C, Aigner E, Datz C. Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. J Clin Med 2020;9:E1065. [PMID: 32283679 DOI: 10.3390/jcm9041065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
613 Kehagias D, Mulita F, Drakos N, Seretis F, Liolis E, Kehagias I. Bariatric surgery: blessing or sometimes curse for the liver? Prz Menopauzalny 2021;20:108-11. [PMID: 34321990 DOI: 10.5114/pm.2021.106062] [Reference Citation Analysis]
614 Mantovani A, Dauriz M, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. Metabolism 2018;87:1-12. [DOI: 10.1016/j.metabol.2018.06.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 10.8] [Reference Citation Analysis]
615 Liu SS, Ma XF, Zhao J, Du SX, Zhang J, Dong MZ, Xin YN. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. Lipids Health Dis 2020;19:118. [PMID: 32475354 DOI: 10.1186/s12944-020-01288-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
616 Auth PA, da Silva GR, Amaral EC, Bortoli VF, Manzano MI, de Souza LM, Lovato ECW, Ribeiro-Paes JT, Gasparotto Junior A, Lívero FADR. Croton urucurana Baill. Ameliorates Metabolic Associated Fatty Liver Disease in Rats. Front Pharmacol 2022;13:886122. [PMID: 35668935 DOI: 10.3389/fphar.2022.886122] [Reference Citation Analysis]
617 Choe AR, Ryu DR, Kim HY, Lee HA, Lim J, Kim JS, Lee JK, Kim TH, Yoo K. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol 2020;21:50. [PMID: 32066395 DOI: 10.1186/s12882-020-01718-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
618 Lee CH, Choi SH, Chung GE, Park B, Kwak MS. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver Int 2018;38:2091-100. [PMID: 29660233 DOI: 10.1111/liv.13860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
619 Xu Z, Shi L, Li D, Wu Q, Zhang Y, Gao M, Ji A, Jiang Q, Chen R, Zhang R, Chen W, Zheng Y, Cui L. Real ambient particulate matter-induced lipid metabolism disorder: Roles of peroxisome proliferators-activated receptor alpha. Ecotoxicol Environ Saf 2022;231:113173. [PMID: 35007830 DOI: 10.1016/j.ecoenv.2022.113173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
620 Aydın B, Winters SJ. Sex Hormone-Binding Globulin in Children and Adolescents. J Clin Res Pediatr Endocrinol 2016;8:1-12. [PMID: 26761949 DOI: 10.4274/jcrpe.2764] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
621 Yaskolka Meir A, Rinott E, Tsaban G, Zelicha H, Kaplan A, Rosen P, Shelef I, Youngster I, Shalev A, Blüher M, Ceglarek U, Stumvoll M, Tuohy K, Diotallevi C, Vrhovsek U, Hu F, Stampfer M, Shai I. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut 2021;70:2085-95. [PMID: 33461965 DOI: 10.1136/gutjnl-2020-323106] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 30.0] [Reference Citation Analysis]
622 Formichi C, Nigi L, Grieco GE, Maccora C, Fignani D, Brusco N, Licata G, Sebastiani G, Dotta F. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. Int J Mol Sci 2021;22:7716. [PMID: 34299336 DOI: 10.3390/ijms22147716] [Reference Citation Analysis]
623 Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther 2017;34:1291-326. [PMID: 28526997 DOI: 10.1007/s12325-017-0556-1] [Cited by in Crossref: 246] [Cited by in F6Publishing: 217] [Article Influence: 49.2] [Reference Citation Analysis]
624 Al Humayed S. Protective and therapeutic effects of Crataegus aronia in non-alcoholic fatty liver disease. Archives of Physiology and Biochemistry 2016;123:23-30. [DOI: 10.1080/13813455.2016.1205097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
625 Guan J, Wang G, Yang Q, Chen C, Deng J, Gu X, Zhu H. Natural Killer T Cells in Various Mouse Models of Hepatitis. Biomed Res Int 2021;2021:1782765. [PMID: 33506011 DOI: 10.1155/2021/1782765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
626 Shen B, Zhao C, Wang Y, Peng Y, Cheng J, Li Z, Wu L, Jin M, Feng H. Aucubin inhibited lipid accumulation and oxidative stress via Nrf2/HO-1 and AMPK signalling pathways. J Cell Mol Med 2019;23:4063-75. [PMID: 30950217 DOI: 10.1111/jcmm.14293] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
627 Nazmy EA, El-khouly OA, Atef H, Said E. Sulforaphane protects against sodium valproate–induced acute liver injury. Can J Physiol Pharmacol 2017;95:420-6. [DOI: 10.1139/cjpp-2016-0447] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
628 Xin Z, Liu S, Niu J, Xu M, Wang T, Lu J, Chen Y, Wang W, Ning G, Bi Y, Xu Y, Li M, Zhao Z. The association of low-grade albuminuria with incident non-alcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycaemia status. Liver Int 2021;41:101-9. [PMID: 32840963 DOI: 10.1111/liv.14649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
629 D'silva M, Cho JY, Han H, Yoon Y, Lee HW, Lee JS, Lee B, Kim M. Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma. Surgical Oncology 2022;41:101730. [DOI: 10.1016/j.suronc.2022.101730] [Reference Citation Analysis]
630 Wattacheril J. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:141-9. [PMID: 32033760 DOI: 10.1016/j.gtc.2019.10.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
631 Sun Z, Cao H, Liu QS, Liang Y, Fiedler H, Zhang J, Zhou Q, Jiang G. 4-Hexylphenol influences adipogenic differentiation and hepatic lipid accumulation in vitro. Environ Pollut 2021;268:115635. [PMID: 33045592 DOI: 10.1016/j.envpol.2020.115635] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
632 Varghese DS, Ali BR. Pathological Crosstalk Between Oxidized LDL and ER Stress in Human Diseases: A Comprehensive Review. Front Cell Dev Biol 2021;9:674103. [PMID: 34124059 DOI: 10.3389/fcell.2021.674103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
633 Saadati S, Hatami B, Yari Z, Shahrbaf MA, Eghtesad S, Mansour A, Poustchi H, Hedayati M, Aghajanpoor-Pasha M, Sadeghi A, Hekmatdoost A. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr 2019;73:441-9. [PMID: 30610213 DOI: 10.1038/s41430-018-0382-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
634 Im HJ, Hwang SJ, Lee JS, Lee SB, Kang JY, Son CG. Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. Nutrients 2020;12:E2433. [PMID: 32823613 DOI: 10.3390/nu12082433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
635 Shu T, Song X, Cui X, Ge W, Gao R, Wang J. Fc Gamma Receptor IIb Expressed in Hepatocytes Promotes Lipid Accumulation and Gluconeogenesis. Int J Mol Sci 2018;19:E2932. [PMID: 30261661 DOI: 10.3390/ijms19102932] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
636 Li Z, Lin M, Liu C, Chen Z, Wang D, Shi X, Yang S, Li XJ. The rs4686434 variant in the fetuin B (FETUB) locus is associated with intrahepatic triglyceride content in obese Chinese adults. J Diabetes 2018;10:916-25. [PMID: 29671945 DOI: 10.1111/1753-0407.12774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
637 Freag MS, Namgung B, Reyna Fernandez ME, Gherardi E, Sengupta S, Jang HL. Human Nonalcoholic Steatohepatitis on a Chip. Hepatol Commun 2021;5:217-33. [PMID: 33553970 DOI: 10.1002/hep4.1647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
638 Minamikawa T, Ichimura-Shimizu M, Takanari H, Morimoto Y, Shiomi R, Tanioka H, Hase E, Yasui T, Tsuneyama K. Molecular imaging analysis of microvesicular and macrovesicular lipid droplets in non-alcoholic fatty liver disease by Raman microscopy. Sci Rep 2020;10:18548. [PMID: 33122711 DOI: 10.1038/s41598-020-75604-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
639 Asif S, Morrow NM, Mulvihill EE, Kim KH. Understanding Dietary Intervention-Mediated Epigenetic Modifications in Metabolic Diseases. Front Genet 2020;11:590369. [PMID: 33193730 DOI: 10.3389/fgene.2020.590369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
640 Mehrdoost S, Yaghmaei P, Jafary H, Ebrahim-Habibi A. The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease. Iran J Basic Med Sci 2021;24:451-9. [PMID: 34094026 DOI: 10.22038/ijbms.2021.52239.11822] [Reference Citation Analysis]
641 Mikami K, Endo T, Sawada N, Igarashi G, Kimura M, Hasegawa T, Iino C, Tomita H, Sawada K, Nakaji S, Matsuzaka M, Torok NJ, Fukuda S. Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population. Cytokine 2020;126:154927. [PMID: 31756645 DOI: 10.1016/j.cyto.2019.154927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
642 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
643 Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis. 2016;246:13-20. [PMID: 26748347 DOI: 10.1016/j.atherosclerosis.2015.12.028] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
644 Yang M, Xu Y, Hu C, Zhang S, Kuang M, Zou Y. Association between hypertriglyceridemic-waist phenotype and non-alcoholic fatty liver disease: a general population-based study. Lipids Health Dis 2022;21:50. [PMID: 35655216 DOI: 10.1186/s12944-022-01660-8] [Reference Citation Analysis]
645 Vahid F, Shivappa N, Hekmatdoost A, R Hebert J, Poustchi H, Shamsipour A, Eslamparast T, Meibodi M, Rahmani D. Association of Pro-inflammatory Dietary Intake and Non-Alcoholic Fatty Liver Disease: Findings from Iranian case-control study. Int J Vitam Nutr Res 2018;88:144-50. [PMID: 30887902 DOI: 10.1024/0300-9831/a000571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
646 Tsuji Y, Kaji K, Kitade M, Kaya D, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Moriya K, Akahane T, Yoshiji H. Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. Microorganisms 2020;8:E925. [PMID: 32575352 DOI: 10.3390/microorganisms8060925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
647 Wijarnpreecha K, Lou S, Watthanasuntorn K, Kroner PT, Cheungpasitporn W, Lukens FJ, Pungpapong S, Keaveny AP, Ungprasert P. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:601-8. [PMID: 31567712 DOI: 10.1097/MEG.0000000000001541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
648 Mayer C, Côme M, Blanckaert V, Chini Zittelli G, Faraloni C, Nazih H, Ouguerram K, Mimouni V, Chénais B. Effect of Carotenoids from Phaeodactylum tricornutum on Palmitate-Treated HepG2 Cells. Molecules 2020;25:E2845. [PMID: 32575640 DOI: 10.3390/molecules25122845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
649 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy. Intern Med 2019;58:375-80. [PMID: 30210131 DOI: 10.2169/internalmedicine.1587-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
650 Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour J, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 2021;18:24-39. [DOI: 10.1038/s41575-020-00366-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
651 Sun S, Yang Q, Zhou Q, Cao W, Yu S, Zhan S, Sun F. Long-term exposure to air pollution, habitual physical activity and risk of non-alcoholic fatty liver disease: A prospective cohort study. Ecotoxicol Environ Saf 2022;235:113440. [PMID: 35344898 DOI: 10.1016/j.ecoenv.2022.113440] [Reference Citation Analysis]
652 Yu H, Jiang X, Dong F, Zhang F, Ji X, Xue M, Yang F, Chen J, Hu X, Bao Z. Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway. Exp Cell Res 2021;405:112689. [PMID: 34107274 DOI: 10.1016/j.yexcr.2021.112689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
653 El Khoury D, Pauley RJ, Berseth CL. Dietary approaches to managing nonalcoholic fatty liver disease. Nurse Pract 2021;46:19-26. [PMID: 33399334 DOI: 10.1097/01.NPR.0000731560.23509.ff] [Reference Citation Analysis]
654 Jiang X, Li X, Zhu C, Sun J, Tian L, Chen W, Bai W. The target cells of anthocyanins in metabolic syndrome. Critical Reviews in Food Science and Nutrition 2018;59:921-46. [DOI: 10.1080/10408398.2018.1491022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
655 Byrne CD, Targher G. Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed. Gut 2021:gutjnl-2021-325965. [PMID: 34509980 DOI: 10.1136/gutjnl-2021-325965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
656 Kolb R, Zhang W. Obesity and Breast Cancer: A Case of Inflamed Adipose Tissue. Cancers (Basel) 2020;12:E1686. [PMID: 32630445 DOI: 10.3390/cancers12061686] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
657 Patel PJ, Hayward KL, Rudra R, Horsfall LU, Hossain F, Williams S, Johnson T, Brown NN, Saad N, Clouston AD, Stuart KA, Valery PC, Irvine KM, Russell AW, Powell EE. Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management. Medicine (Baltimore) 2017;96:e6761. [PMID: 28658094 DOI: 10.1097/MD.0000000000006761] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
658 Jarmakiewicz-czaja S, Sokal A, Pardak P, Filip R, Granito A. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-13. [DOI: 10.1155/2022/4344905] [Reference Citation Analysis]
659 Ooi GJ, Earnest A, Kemp WW, Burton PR, Laurie C, Majeed A, Johnson N, McLean C, Roberts SK, Brown WA. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. Int J Obes (Lond) 2018;42:1900-11. [PMID: 29463916 DOI: 10.1038/s41366-018-0007-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
660 Shen C, Pan Z, Wu S, Zheng M, Zhong C, Xin X, Lan S, Zhu Z, Liu M, Wu H, Huang Q, Zhang J, Liu Z, Si Y, Tu H, Deng Z, Yu Y, Liu H, Zhong Y, Guo J, Cai J, Xian S. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway. J Ethnopharmacol 2021;279:114340. [PMID: 34171397 DOI: 10.1016/j.jep.2021.114340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
661 Ahmed IA, Mikail MA, Mustafa MR, Ibrahim M, Othman R. Lifestyle interventions for non-alcoholic fatty liver disease. Saudi J Biol Sci 2019;26:1519-24. [PMID: 31762620 DOI: 10.1016/j.sjbs.2018.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
662 Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med 2020;37:1793-806. [PMID: 32619031 DOI: 10.1111/dme.14356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
663 Wild SH, Morling JR, McAllister DA, Kerssens J, Fischbacher C, Parkes J, Roderick PJ, Sattar N, Byrne CD. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. J Hepatol. 2016;64:1358-1364. [PMID: 26812073 DOI: 10.1016/j.jhep.2016.01.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
664 Du J, Ren W, Zhang Q, Fu N, Han F, Cui P, Li W, Kong L, Zhao S, Wang R, Zhang Y, Yang L, Kong L, Nan Y. Heme Oxygenase-1 Suppresses Wnt Signaling Pathway in Nonalcoholic Steatohepatitis-Related Liver Fibrosis. Biomed Res Int 2020;2020:4910601. [PMID: 32461992 DOI: 10.1155/2020/4910601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
665 Harlow KE, Africa JA, Wells A, Belt PH, Behling CA, Jain AK, Molleston JP, Newton KP, Rosenthal P, Vos MB, Xanthakos SA, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 2018;198:76-83.e2. [PMID: 29661561 DOI: 10.1016/j.jpeds.2018.02.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
666 Luan X, Tian X, Zhang H, Huang R, Li N, Chen P, Wang R. Exercise as a prescription for patients with various diseases. J Sport Health Sci 2019;8:422-41. [PMID: 31534817 DOI: 10.1016/j.jshs.2019.04.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 25.3] [Reference Citation Analysis]
667 Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. Int J Mol Sci. 2019;20. [PMID: 31212642 DOI: 10.3390/ijms20112841] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
668 Lonardo A, Nascimbeni F, Ponz de Leon M. Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? Eur Respir J 2017;49:1700546. [DOI: 10.1183/13993003.00546-2017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
669 Lastuvkova H, Faradonbeh FA, Schreiberova J, Hroch M, Mokry J, Faistova H, Nova Z, Hyspler R, Igreja Sa IC, Nachtigal P, Stefela A, Pavek P, Micuda S. Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis. Int J Mol Sci 2021;22:6468. [PMID: 34208774 DOI: 10.3390/ijms22126468] [Reference Citation Analysis]
670 Eslam M, George J. Genetic Insights for Drug Development in NAFLD. Trends Pharmacol Sci. 2019;40:506-516. [PMID: 31160124 DOI: 10.1016/j.tips.2019.05.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
671 Tuzer C, Sertbas Y, Duman E, Komoglu S, Kan O, Ay S, Yigit A, Sertbas M, Okuroglu N, Ozen B, Dalbeler A, Ozdemir A. The role of mean platelet volume in nonalcoholic fatty liver disease without cardiovascular comorbidities, obesity and diabetes mellitus. Eur J Gastroenterol Hepatol 2021;33:1222-8. [PMID: 34397640 DOI: 10.1097/MEG.0000000000002189] [Reference Citation Analysis]
672 Shi J, Wang Z, Zhang W, Niu Y, Lin N, Li X, Zhang H, Ning G, Fan J, Qin L, Su Q, Yang Z. Neck circumference as an independent predictor for NAFLD among postmenopausal women with normal body mass index. Nutr Metab (Lond) 2021;18:30. [PMID: 33731171 DOI: 10.1186/s12986-021-00562-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
673 Zhai T, Chen Q, Xu J, Jia X, Xia P. Prevalence and Trends in Low Bone Density, Osteopenia and Osteoporosis in U.S. Adults With Non-Alcoholic Fatty Liver Disease, 2005–2014. Front Endocrinol 2022;12:825448. [DOI: 10.3389/fendo.2021.825448] [Reference Citation Analysis]
674 Fiorentino TV, Miceli S, Succurro E, Sciacqua A, Andreozzi F, Sesti G. Nonalcoholic fatty liver disease is associated with a decreased myocardial mechano-energetic efficiency. J Intern Med 2021;289:221-31. [PMID: 32633873 DOI: 10.1111/joim.13155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
675 Wang L, Zhu X, Sun X, Yang X, Chang X, Xia M, Lu Y, Xia P, Yan H, Bian H, Gao X. FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c. Lipids Health Dis 2019;18:197. [PMID: 31729980 DOI: 10.1186/s12944-019-1132-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
676 Targher G, Mantovani A, Grander C, Foco L, Motta B, Byrne CD, Pramstaller PP, Tilg H. Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. Nutr Metab Cardiovasc Dis 2021;31:3464-73. [PMID: 34627696 DOI: 10.1016/j.numecd.2021.08.037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
677 Wijarnpreecha K, Panjawatanan P, Lekuthai N, Thongprayoon C, Cheungpasitporn W, Ungprasert P. Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis. Liver Int 2017;37:906-18. [DOI: 10.1111/liv.13329] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
678 Chen X, Wen H, Li Q, Shen L, Luo X, Zhou B, Guo R. Quantification of liver fat deposition in obese and diabetic patients: A pilot study on the correlation with myocardium and periapical fat content☆. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.005] [Reference Citation Analysis]
679 Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:128-41. [PMID: 31696690 DOI: 10.3350/cmh.2019.0001n] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
680 Selvakumar PKC, Kabbany MN, Nobili V, Alkhouri N. Nonalcoholic Fatty Liver Disease in Children. Pediatric Clinics of North America 2017;64:659-75. [DOI: 10.1016/j.pcl.2017.01.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
681 Canbay A, Kälsch J, Neumann U, Rau M, Hohenester S, Baba HA, Rust C, Geier A, Heider D, Sowa JP. Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective. PLoS One 2019;14:e0214436. [PMID: 30913263 DOI: 10.1371/journal.pone.0214436] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
682 Huang R, Guo F, Li Y, Liang Y, Li G, Fu P, Ma L. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis. Phytomedicine 2021;92:153739. [PMID: 34592488 DOI: 10.1016/j.phymed.2021.153739] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
683 Fabrizi F, Messa P. Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 2018;11:1135-42. [PMID: 30309263 DOI: 10.1080/17512433.2018.1534202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
684 Thandra KC, Barsouk A, Saginala K, Aluru JS, Rawla P, Barsouk A. Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. Clin Exp Hepatol 2020;6:289-94. [PMID: 33511275 DOI: 10.5114/ceh.2020.102153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
685 Haas SL, Löfgren P, Stål P, Hoffstedt J. Glucagon and Liver Fat are Downregulated in Response to Very Low-calorie Diet in Patients with Obesity and Type-2 Diabetes. Exp Clin Endocrinol Diabetes 2022;130:55-60. [PMID: 32767285 DOI: 10.1055/a-1220-6160] [Reference Citation Analysis]
686 Mosca A, Nobili V, De Vito R, Crudele A, Scorletti E, Villani A, Alisi A, Byrne CD. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol. 2017;66:1031-1036. [PMID: 28214020 DOI: 10.1016/j.jhep.2016.12.025] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 15.6] [Reference Citation Analysis]
687 Senesi P, Ferrulli A, Luzi L, Terruzzi I. Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction. Int J Mol Sci 2021;22:7772. [PMID: 34360538 DOI: 10.3390/ijms22157772] [Reference Citation Analysis]
688 Scheja L, Heeren J. Metabolic interplay between white, beige, brown adipocytes and the liver. J Hepatol. 2016;64:1176-1186. [PMID: 26829204 DOI: 10.1016/j.jhep.2016.01.025] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 11.8] [Reference Citation Analysis]
689 Mazhar K. The Future of Nonalcoholic Fatty Liver Disease Treatment. Med Clin North Am 2019;103:57-69. [PMID: 30466676 DOI: 10.1016/j.mcna.2018.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
690 Di Costanzo A, Ronca A, D'Erasmo L, Manfredini M, Baratta F, Pastori D, Di Martino M, Ceci F, Angelico F, Del Ben M, Pavanello C, Turri M, Calabresi L, Favari E, Arca M. HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines 2020;8:E625. [PMID: 33352841 DOI: 10.3390/biomedicines8120625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
691 Bernal-reyes R, Castro-narro G, Malé-velázquez R, Carmona-sánchez R, González-huezo M, García-juárez I, Chávez-tapia N, Aguilar-salinas C, Aiza-haddad I, Ballesteros-amozurrutia M, Bosques-padilla F, Castillo-barradas M, Chávez-barrera J, Cisneros-garza L, Flores-calderón J, García-compeán D, Gutiérrez-grobe Y, Higuera de la Tijera M, Kershenobich-stalnikowitz D, Ladrón de Guevara-cetina L, Lizardi-cervera J, López-cossio J, Martínez-vázquez S, Márquez-guillén E, Méndez-sánchez N, Moreno-alcantar R, Poo-ramírez J, Ramos-martínez P, Rodríguez-hernández H, Sánchez-ávila J, Stoopen-rometti M, Torre-delgadillo A, Torres-villalobos G, Trejo-estrada R, Uribe-esquivel M, Velarde-ruiz Velasco J. The Mexican consensus on nonalcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 2019;84:69-99. [DOI: 10.1016/j.rgmxen.2019.02.003] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
692 Danford CJ, Sanchez JE, Corey KE. Managing the Burden of Non-NASH NAFLD. Curr Hepatol Rep 2017;16:326-34. [PMID: 29503789 DOI: 10.1007/s11901-017-0371-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
693 Nelidova AV, Livzan MA, Nikolaev NA, Krolevets TS. Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy. Racionalʹnaâ farmakoterapiâ v kardiologii 2022;17:880-8. [DOI: 10.20996/1819-6446-2021-12-14] [Reference Citation Analysis]
694 Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Insomnia and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Postgrad Med 2017;63:226-31. [PMID: 28862239 DOI: 10.4103/jpgm.JPGM_140_17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
695 Bellan M, Colletta C, Barbaglia MN, Salmi L, Clerici R, Mallela VR, Castello LM, Saglietti G, Carnevale Schianca GP, Minisini R, Pirisi M. Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms. Diabetes Metab J 2019;43:700-10. [PMID: 31694082 DOI: 10.4093/dmj.2018.0201] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
696 Gao Z, Dai L, Zhang H, Cheng L. Screening Potential Drugs for the Development of NAFLD Based on Drug Perturbation Gene Set. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/7606716] [Reference Citation Analysis]
697 Kim NH, Jung YS, Park JH, Park DI, Sohn CI. Impact of nonalcoholic fatty liver disease on the risk of metachronous colorectal neoplasia after polypectomy. Korean J Intern Med 2021;36:557-67. [PMID: 32630984 DOI: 10.3904/kjim.2019.360] [Reference Citation Analysis]
698 Abenavoli L, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(31): 7006-7016 [PMID: 27610012 DOI: 10.3748/wjg.v22.i31.7006] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 94] [Article Influence: 16.3] [Reference Citation Analysis]
699 Atri A, Jiwanmall SA, Nandyal MB, Kattula D, Paravathareddy S, Paul TV, Thomas N, Kapoor N. The Prevalence and Predictors of Non-alcoholic Fatty Liver Disease in Morbidly Obese Women - A Cross-sectional Study from Southern India.Eur Endocrinol. 2020;16:152-155. [PMID: 33117448 DOI: 10.17925/EE.2020.16.2.152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
700 Zhang X, Lin Y, Lin S, Li C, Gao J, Feng Z, Wang J, Zhang J, Zhang H, Zhang Y, Chen X, Chen S, Xu C, Li Y, Yu C, Zeng H. Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction. Hepatol Int 2020;14:828-41. [PMID: 32607732 DOI: 10.1007/s12072-020-10068-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
701 Duan T, Jiang HY, Ling WW, Song B. Noninvasive imaging of hepatic dysfunction: A state-of-the-art review. World J Gastroenterol 2022; 28(16): 1625-1640 [DOI: 10.3748/wjg.v28.i16.1625] [Reference Citation Analysis]
702 Jadeja RN, Upadhyay KK, Devkar RV, Khurana S. Naturally Occurring Nrf2 Activators: Potential in Treatment of Liver Injury. Oxid Med Cell Longev 2016;2016:3453926. [PMID: 28101296 DOI: 10.1155/2016/3453926] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
703 Moroldo M, Munyaka PM, Lecardonnel J, Lemonnier G, Venturi E, Chevaleyre C, Oswald IP, Estellé J, Rogel-Gaillard C. Integrative analysis of blood and gut microbiota data suggests a non-alcoholic fatty liver disease (NAFLD)-related disorder in French SLAdd minipigs. Sci Rep 2020;10:234. [PMID: 31937803 DOI: 10.1038/s41598-019-57127-x] [Reference Citation Analysis]
704 Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71:793-801. [PMID: 31279902 DOI: 10.1016/j.jhep.2019.06.021] [Cited by in Crossref: 295] [Cited by in F6Publishing: 289] [Article Influence: 98.3] [Reference Citation Analysis]
705 Kumar DP, Santhekadur PK, Seneshaw M, Mirshahi F, Uram-Tuculescu C, Sanyal AJ. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Hepatology 2019;69:1520-34. [PMID: 30394550 DOI: 10.1002/hep.30346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
706 Ruan J, Guo J, Huang Y, Mao Y, Yang Z, Zuo Z. Adolescent exposure to environmental level of PCBs (Aroclor 1254) induces non-alcoholic fatty liver disease in male mice. Environmental Research 2020;181:108909. [DOI: 10.1016/j.envres.2019.108909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
707 Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 2018;44:457-64. [PMID: 30266577 DOI: 10.1016/j.diabet.2018.09.005] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 25.8] [Reference Citation Analysis]
708 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
709 Sayiner M, Lam B, Golabi P, Younossi ZM. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2018;11:1756284818811508. [PMID: 30479664 DOI: 10.1177/1756284818811508] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
710 Badolati N, Masselli R, Sommella E, Sagliocchi S, Di Minno A, Salviati E, Campiglia P, Dentice M, Tenore GC, Stornaiuolo M, Novellino E. The Hepatoprotective Effect of Taurisolo, a Nutraceutical Enriched in Resveratrol and Polyphenols, Involves Activation of Mitochondrial Metabolism in Mice Liver. Antioxidants (Basel) 2020;9:E410. [PMID: 32403305 DOI: 10.3390/antiox9050410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
711 Latif MU, Schmidt GE, Mercan S, Rahman R, Gibhardt CS, Stejerean-Todoran I, Reutlinger K, Hessmann E, Singh SK, Moeed A, Rehman A, Butt UJ, Bohnenberger H, Stroebel P, Bremer SC, Neesse A, Bogeski I, Ellenrieder V. NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. Gut 2022:gutjnl-2021-325013. [PMID: 35365570 DOI: 10.1136/gutjnl-2021-325013] [Reference Citation Analysis]
712 Yang M, Geng CA, Liu X, Guan M. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines 2021;9:1405. [PMID: 34680522 DOI: 10.3390/biomedicines9101405] [Reference Citation Analysis]
713 Pacifico L, Perla FM, Roggini M, Andreoli G, D'Avanzo M, Chiesa C. A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths. J Clin Med 2019;8:E868. [PMID: 31213030 DOI: 10.3390/jcm8060868] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
714 Gallo-Ebert C, Francisco J, Liu HY, Draper R, Modi K, Hayward MD, Jones BK, Buiakova O, McDonough V, Nickels JT Jr. Mice lacking ARV1 have reduced signs of metabolic syndrome and non-alcoholic fatty liver disease. J Biol Chem 2018;293:5956-74. [PMID: 29491146 DOI: 10.1074/jbc.RA117.000800] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
715 Tommasi S, Besaratinia A. DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E2791. [PMID: 31387232 DOI: 10.3390/ijerph16152791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
716 Hussain M, Habib-Ur-Rehman, Akhtar L. Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients. Pak J Med Sci 2017;33:931-6. [PMID: 29067068 DOI: 10.12669/pjms.334.12571] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
717 Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa R, Huiban L, Cojocariu C, Singeap AM, Girleanu I, Chiriac S, Stanciu C. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Can J Gastroenterol Hepatol 2020;2020:6638306. [PMID: 33425804 DOI: 10.1155/2020/6638306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
718 Wang R, Dai L, Zhong Y, Xie G. Usefulness of the triglyceride glucose-body mass index in evaluating nonalcoholic fatty liver disease: insights from a general population. Lipids Health Dis 2021;20:77. [PMID: 34321005 DOI: 10.1186/s12944-021-01506-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
719 Gabbia D, Roverso M, Guido M, Sacchi D, Scaffidi M, Carrara M, Orso G, Russo FP, Floreani A, Bogialli S, De Martin S. Western Diet-Induced Metabolic Alterations Affect Circulating Markers of Liver Function before the Development of Steatosis. Nutrients 2019;11:E1602. [PMID: 31311123 DOI: 10.3390/nu11071602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
720 Kim S, Chang Y, Sung E, Kim CH, Yun KE, Jung HS, Shin H, Ryu S. Non-alcoholic fatty liver disease and the development of nephrolithiasis: A cohort study. PLoS One 2017;12:e0184506. [PMID: 29073130 DOI: 10.1371/journal.pone.0184506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
721 Jirapinyo P, Thompson CC. Treatment of NASH with Gastric Bypass. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
722 Kumar S, Wong R, Newberry C, Yeung M, Peña JM, Sharaiha RZ. Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD. Hepatology 2021;74:3472-8. [PMID: 34324727 DOI: 10.1002/hep.32081] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
723 Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904. [PMID: 29886156 DOI: 10.1016/j.jhep.2018.05.036] [Cited by in Crossref: 381] [Cited by in F6Publishing: 362] [Article Influence: 95.3] [Reference Citation Analysis]
724 Carstensen-Kirberg M, Hatziagelaki E, Tsiavou A, Chounta A, Nowotny P, Pacini G, Dimitriadis G, Roden M, Herder C. Sfrp5 associates with beta-cell function in humans. Eur J Clin Invest 2016;46:535-43. [PMID: 27019073 DOI: 10.1111/eci.12629] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
725 He Z, Li X, Yang H, Wu P, Wang S, Cao D, Guo X, Xu Z, Gao J, Zhang W, Luo X. Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front Nutr 2021;8:745609. [PMID: 34595203 DOI: 10.3389/fnut.2021.745609] [Reference Citation Analysis]
726 Olaniyi KS, Amusa OA. Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin-nicotinamide-induced diabetic rats. Biomed Pharmacother 2020;128:110226. [PMID: 32460191 DOI: 10.1016/j.biopha.2020.110226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
727 Kwak M, Kim E, Jang EJ, Lee C. The association of non-alcoholic fatty liver disease with lung function: A survey design analysis using propensity score: NAFLD and lung function. Respirology 2018;23:82-8. [DOI: 10.1111/resp.13127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
728 Squillace N, Soria A, Bozzi G, Gori A, Bandera A. Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV. Expert Rev Gastroenterol Hepatol 2019;13:643-50. [PMID: 31081390 DOI: 10.1080/17474124.2019.1614913] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
729 Guo F, Xu S, Zhu Y, Zheng X, Lu Y, Tu J, He Y, Jin L, Li Y. PPARγ Transcription Deficiency Exacerbates High-Fat Diet-Induced Adipocyte Hypertrophy and Insulin Resistance in Mice. Front Pharmacol 2020;11:1285. [PMID: 32973516 DOI: 10.3389/fphar.2020.01285] [Reference Citation Analysis]
730 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.Ann Hepatol. 2020;19:674-690. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
731 Jepsen P, Turati F, La Vecchia C. NAFLD and cancer: More cause for concern? Journal of Hepatology 2018;68:10-2. [DOI: 10.1016/j.jhep.2017.10.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
732 Arrese M, Feldstein AE. Nash-Related Cirrhosis: An Occult Liver Disease Burden. Hepatol Commun. 2017;1:84-86. [PMID: 29335681 DOI: 10.1002/hep4.1033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
733 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Reference Citation Analysis]
734 Hendrikx T, Binder CJ. Oxidation-Specific Epitopes in Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2020;11:607011. [PMID: 33362721 DOI: 10.3389/fendo.2020.607011]